Elliot M. Frohman, M.D., Ph.D. - UT Southwestern Medical ... Elliot Frohman.pdf · Accelerated Cure Project for Multiple Sclerosis Boston, MA 2012-14 US News and World Report Top

Elliot M. Frohman, M.D., Ph.D.

Elliot Mark Frohman, M.D., Ph.D., FAAN

Professor of Neurology and Neurotherapeutics & Ophthalmology (with Tenure) Irene Wadel and Robert Atha Jr. Distinguished Chair in Neurology

Kenney Marie Dixon-Pickens Distinguished Professorship in MS Research Holder of the Cain Foundation Endowment for MS Research

Department of Neurology and Neurotherapeutics

University of Texas Southwestern Medical School 5323 Harry Hines Blvd.

Dallas, Texas 75390 (Tele:214-645-0555; Fax:214-645-0556)

[email protected]

Home Address: 213 Chestnut Lane, Coppell, Texas 75019 Date and: April 3, 1959 Place of Birth: New York, New York Marital Status: Married to Teresa Carol Frohman Children: Alexander, Ashley, Audrey, & Benjamin EDUCATION: Fellowship Neurophysiology/Neuro-otology-Oculomotor control Drs. David Cornblath & David Zee Department of Neurology Johns Hopkins Hospital 1994-1995 Chief Resident Department of Neurology Johns Hopkins Hospital 1993-1994 Residency Department of Neurology Johns Hopkins Hospital 1991-1994 Internship Department of Medicine Baptist Memorial Hospital University of Tennessee Memphis, Tennessee 1990-1991 Medical School University of California, Irvine Alpha Omega Alpha 1990


2

Graduate School PhD.-Anatomy & Neurobiology-July 1988 University of California, Irvine The Regulation of Astrocyte Mediated Intracerebral Immune Responses Undergraduate BA-Biochemistry & Cell Biology (minor in Drama) Revelle College University of California, San Diego cum laude 1982 EMT/EKG Western College, Van Nuys, California 1978 RESEARCH TRAINING: 1979 Laboratory of Dr. Toni Hugli Undergraduate Research Fellowship Scripps Clinic & Research Foundation Department of Molecular Immunology La Jolla, California Complement components C3a and C5a in disease 1979 Laboratory of Dr. Sun Lee Undergraduate Research Project Department of Surgery University of California, San Diego School of Medicine Experimental microvascular surgery 1985-1988 Laboratory of Dr. Edward G. Jones (Thesis Chairman) Department of Anatomy & Neurobiology University of California, Irvine Neuroanatomical techniques Laboratory of Dr. Stanley van den Noort Department of Neurology University of California, Irvine Neuroimmunology of multiple sclerosis Laboratory of Dr. Sudhir Gupta Division of Molecular Immunology University of California, Irvine Molecular & Cellular Immunology


3

Laboratory of Dr. D.C. Gajdusek National Institutes of Health Laboratory of Central Nervous System Studies NINCDS HIV infection of human glial cell cultures Laboratory of Dr. C.E. Ribak Department of Anatomy & Neurobiology Laboratory of Dr. Gary Lynch Department of Psychobiology University of California, Irvine Calcium dependent proteases in seizure sensitive gerbils LICENSURE: Board Certification American Board of Psychiatry and Neurology 5/95 #41248 Board Certification American Board of Psychiatry and Neurology 9/2005 #41248 (recertification) State Licensure Texas #J8241 ACLS Advanced cardiac life support certification (every 2 yrs) 2008-2010 ACADEMIC APPOINTMENTS: Asst. Professor Departments of Neurology and Ophthalmology University of Texas Southwestern Medical School 1995-2000 Assoc. Professor Department of Neurology and Ophthalmology University of Texas Southwestern Medical School 2000-2004 Professor Departments of Neurology and Ophthalmology University of Texas Southwestern Medical School 2004-with Tenure


4

Professor (Adjunct) Distinguished Visiting Professor Charles University School of Medicine Prague, Czech Republic 2009- Professor (Adjunct) School of Behavioral and Brain Sciences The University of Texas at Dallas 2013- Professor (Adjunct) School of BioEngineering The University of Texas at Dallas 2013- Director Multiple Sclerosis Program and Clinical Center for Multiple Sclerosis University of Texas Southwestern Medical School 1995-present Director Comprehensive MS Treatment Training Program Supported by a United States Congressional Bill Author: E.M. Frohman Sponsor: Senator Kay Baily Hutchison (R-Texas) A National Advanced Education Initiative 2001-2006 (over 900 physicians trained) Co-Director Neurology Medical Student Education University of Texas Southwestern Medical School 1996-2004 Endowed Professorship Holder of the Kenney Marie Dixon-Pickens 1997-Present Distinguished Professorship in MS Research Endowed Professorship Holder of the Irene Wadel and Robert Atha Professorship 1999-2000 In Neurology (converted to Distinguished Chair in 2000) Distinguished Chair Holder of the Irene Wadel and Robert Atha Distinguished 2000-Present Chair in Neurology MS Center Endowment Holder of the Cain Foundation Endowment for MS 2005-Present MS Research Fund Holder of the Marge and Ed Tagg Multiple Sclerosis Fund In Honor of Elliot and Teresa Frohman


5

Director Garry McKinney Fund for MS Research Director Hawn Foundation Fund for MS Research Director Jean Ann and Steve Brock Fund for Medical Science (MS) Director Once Upon A Time Fund for MS Director Gilson Logenbaugh MS Research Fund Director Viragh Foundation Fund for MS Director DAD’s Foundation Fund for MS Research Director Dale Energy Corporation Fund for MS Research Director Total Life Care (TLC) Clinic Fund (supported by the National MS Society and various private donors. Director Holder of the Barbara Cummins MS Research Fund Director Marge and Edmund Tagg Fund for MS Research PROFESSIONAL MEMBERSHIPS: 1994-present American Academy of Neurology (Fellow) 2002-present American Neurological Association 1995-present Texas Medical Association 1989-1993 Member-International Society of Neuroimmunology HONORS: 1977-1979 Dean's List University of Southern California 1977-1979 Alpha Epsilon Delta Premedical Honor Society University of Southern California 1979-1982 Provost's Honor List


6

University of California, San Diego 1979 Undergraduate Immunology Research Fellowship Scripps Clinic and Research Foundation La Jolla, California 1982 cum laude-Biochemistry & Cell Biology University of California, San Diego 1986 J.M. Foundation Drug & Alcohol Studies Scholarship University of California, San Diego 1986 J.M. Foundation Drug & Alcohol Studies Scholarship Memphis Mental Health Institute University of Tennessee School of Medicine 1986 March of Dimes Birth Defects Foundation Medical Student Research Fellowship 1986 Parkinson's Disease Foundation Medical Student Research Fellowship 1986-1988 Graduate Research Fellowships Departments of Neurology, Anatomy & Neurobiology 1987 Patent Fund Research Award School of Biological Sciences University of California, Irvine 1987 National Institutes of Health Summer Research Fellowship Laboratory of Nobel Laureate Dr. D.C. Gajdusek 1987 National Institute of Neurological, Communicative Disorders & Stroke Exceptional Employee Award Laboratory of Central Nervous System Studies National Institutes of Health 1987 Sigma Xi Research Society Graduate Research Grant in Aid


7

1988 U.C. Regents Dissertation Fellowship University of California, Irvine 1988-1990 University of California, Irvine Division of Biological Sciences MD/PhD Fellowship 1988 Myasthenia Gravis Foundation Medical Student Research Fellowship 1989 National Multiple Sclerosis Society Traveling Investigatorship Award International Congress of Immunology Berlin, West Germany 1989 Nathan Weinstein Memorial Research Award For Basic Science Research University of California, Irvine 1989 Medical Research and Education Society Medical Scientist Scholarship University of California, Irvine 1989 Alpha Omega Alpha University of California, Irvine 1990 The Department of Neurology Award University of California, Irvine 1990 The University of California Academic Excellence Award University of California, Irvine California College of Medicine 1992 Maryland Neurological Society Resident's Research Symposium Basic Science Research Award 1998, 2001, 2002, 2003 The Best Doctors in America 2005-2014 2002 Investigator of the Year Clinical Trials Office University of Texas Southwestern


8

2002 Fellow Status, American Neurological Assocation 2003 Fellow Status, American Academy of Neurology 2003, 2004, 2005, 2006 D Magazine’s Best Doctors in Dallas 2007, 2008, 2009, 2010-14 2005 National MS Society Volunteer Hall of Fame (National) in Clinical Programs-Research. 2007 Dallas Business Journal Health Care Hero Award 2008 Hadassah (Israel) Doctor of the Year 2012 PBS ‘Health Minds Healthy Bodies’

Special Episode on MS (showcasing of UT Southwestern Medical Center’s Clinical Center for Multiple Sclerosis Segment Co-Director

2012 Multiple Sclerosis Physician of Distinction Accelerated Cure Project for Multiple Sclerosis Boston, MA 2012-14 US News and World Report Top 1% of United States Neurologists 2013 Mentored two UT Southwestern Medical Medical Students

(Ethan Meltzer and Peter Squigna) who were awarded one of five ‘Best MS Research in 2013’ Prizes at the European Committee for the Treatment and Research of MS (ECTRIMS) among ~2,000 abstracts submitted Copenhagen Denmark

2014 Mentored two UT Southwestern Medical Medical Students

(Ethan Meltzer and Peter Squigna) who recently were awarded the Department of Neurology &Neurotherapeutics Neurology Award (the first time the award has been given jointly to two recipients; emphasizing the collaborative work of these two outstanding UT students)


9

TEACHING HONORS: 1996,1997, 2004 The Trephined Cranium Faculty Award For Excellence in Teaching Residents (3-time winner) Department of Neurology UT Southwestern Medical School This award is given once a year to the faculty member who was the most outstanding in teaching residents 2000, 2001, 2003, 2004 Outstanding Faculty Teacher (11-time winner) 2005, 2008, 2009, 2011 1st Year Medical School Class 2012, 2013, 2014 Based on Neuroscience Course Lectures (Vestibular System and Cranial Nerves) UT Southwestern Medical School 2009-2014 1st Year Medical Student Favorite Course Neuroscience-Contributor Vestibular System and Cranial Nerves 2008 The American Academy of Neurology (AAN) A.B. Baker Teaching Award (National) 2014 University of Texas Regents Outstanding Teacher Award System-Wide Teaching Award (ROTA) Prize: $25,000 *Special Honorary Fund The Teresa Carol Frohman Multiple Sclerosis Initiative 2014 For Excellence in Patient Care, Education, & Discovery Initiated by Elliot M Frohman, MD, PhD, FAAN In honor of his wife, closest colleague, and collaborator.

The initiative will involve Philanthropic commitments in order to build a fund that will attract and then cultivate the best and brightest MS nurses, physician extenders, social workers, technicians and students. Specifically, we will provide funding awards to facilitate advanced educational initiatives, participation in national and international scientific symposia, and creativity and innovation in patient care, education, and scientific discovery.


10

United States Congresssional Appropriations Bill (E. Frohman, Principal Author) Sponsored by Senator Kay Baily Hutchison (R-Texas) 2001-2006 To establish a National Comprehensive Treatment Training

Program for MS (MSCTTP) Administered through Centers for Disease Control Primary Author of the Bill and Program Director in

conjunction with Teresa C Frohman. Special Endowment The Stanley van den Noort and Elliot M Frohman Mentor Award-2005- Endowment established by Elliot and Teresa Frohman

(rasied the initial corpus of $135,000) to foster the process of faculty mentoring to physician-scientists in training at the University of California at Irvine in honor of their mutual mentor, Dr. Stanley van den Noort.

SPECIAL APPOINTMENTS: 1986 Co-Organizer-Inhibition in the Brain In conjunction with Teresa C Frohman A Satellite Symposium at the 16th Annual Meeting of the Society for Neuroscience 1996 Course Director National MS Society Annual Education Conference 1997 Course Director Current Concepts in Multiple Sclerosis MS Society Professional Education Conference Dallas, Texas 1998 Conference Chairman

A Patient Centered Therapeutic Framework for MS An International Conference On Models of Care Four Seasons Resort,Dallas, Texas

1998 Course Director

A Patient Centered Therapeutic Framework for MS Professional Education Conference (CME)

UT Southwestern Medical Center


11

2000, 2001, 2002, 2003 Course Director-Introduction to Neuro-Urology (CME) American Academy of Neurology Half Day Course 2000-2002 Co-Chairman & Principal Author

MS Disease Altering Therapy Committee MS Council/American Academy of Neurology, Paralyzed Veterans of America, MS Society Consensus Document on MS Treatment

1999-present Course Director MS Journal Club (every other month) (CME)

2001 Course Chairman (CME) MS and the Non-Neurologist UT Southwestern Medical Center Half Day Course 2005- Co-Chairman with Bern Kieseier Global Adherence Project for MS 2,648 Patients; 173 sites; 22 Countries Paris, France Eur J Neurol 2010;18:69-77. 2005 Co-Chairman with Bob Sergott Optical Coherence Tomography in MS (White Paper) New York J Neurol Sci 2007;263:3-14. 2005-2008 Chairman, Clinical Advisory Committee (CAC)

National MS Society, Lone Star Chaper Texas 2009-2012 Executive Committee National Clinical Advisory Board National Multiple Sclerosis Society (New York) PROFESSIONAL EXPERIENCE: 1978 Non-invasive vascular technician West Valley Community Hospital Encino, California 1978 Emergency Room EMT


12

Riverside Hospital Van Nuys, California 1982-1984 Senior Coordinator for Medical Affairs The Winfield Foundation/NY Yankees Baseball Club Fort Lee, New Jersey 1979-1982 Interpersonal Communications Seminar Instructor Community Services Los Angeles Pierce College and Los Angeles City College COMMITTEES, PANELS, and SOCIETIES: 1985-1988 Medical Student Representative Scientific Advisory Panel on Neurology California Medical Association 1986 Member-Liaison Committee Orange County Coroner's Office Orange, California 1989 Medical Student Representative Scientific Advisory Panel on Neurosurgery California Medical Association 1995-present Clinical Advisory Committee National MS Society, North Texas Chapter 1996-2001 National Multiple Sclerosis Clinic Committee New York 1996 Gulf War Syndrome Clinical Committee UT Southwestern Medical Center 1997-present National MS Society Medical Advisory Board New York 1997-2003 Chairman, Medical Advisory Board Yellow Rose Foundation for MS Research 1998- 2003 American Academy of Neurology

Therapeutics & Technology Assessment Committee


13

1998-2002 Member, MS Council on Clinical Practice Guidelines

Washington, D.C. 1998 Aston Center Advisory Committee

UT Southwestern Medical Center

1999 Dept. of Neurology Executive Committee 2002-current Accelerated (formerly Boston) Cure Project for MS Scientific Board of Advisors 2003, 2004 National Board of Medical Examiners Neurology Subject Examination Reviewer 2003-current National Board of Medical Examiners Contributor to Clinical Neurology Subject Examination 2003-current Medical Directors Clinical Operations Committee UT Southwestern Medical Center 2004- Medical School Admissions Committee Interviewer UT Southwestern School of Medicine 2003- Continuing Education Committee UT Southwestern Medical Center RESEARCH SUPPORT: 1996 Hawn Foundation Grant MS Research $50,000.00 1997 Hawn Foundation Grant MS Research $50,000.00 1997 National MS Society Research Grant A Natural History Study of INO in MS $206,000.00 10/97-10/00 1997 Yellow Rose Foundation Research Grant Does IVIg Promote Remyelination In the MLF of MS Patients with INO? A double blind, randomized, prospective, placebo controlled trial.


14

$200,000.00 1997 General Clinical Research Center Investigator Award for Clinical Research University of Texas Southwestern Med Ctr $20,000.00 1997-Present Holder of the Kenney Marie Dixon-Pickens Distinguished Professorship in Multiple Sclerosis Research $500,000.00 Endowment

1998 Yellow Rose Foundation Research Grant

A Randomized Prospective Double Blind Placebo Controlled Dose Escalation Crossover Trial of Oral Sildenafil (Viagra) in Patients with MS & Sexual Dysfunction $62,000.00

1998 Hawn Foundation Grant MS Research $50,000.00 1999 IFNb1a (Avonex) in Advanced Forms of Relapsing MS A Retrospective View Sponsored by Biogen $23,000.00 1999 Holder of the Irene Wadel and Robert Atha Professorship in Neurology 1999 Yellow Rose Foundation Antibiotic therapy for C. pneumoniae of the CNS in MS $145,000.00 2000-Present Holder of the Irene Wadel and Robert Atha Distinguished Chair in Neurology 2000 Antibiotic Therapy for C. pneumoniae in MS

National MS Society-Collaboration with Dr. Ram Sriram $691,906

2001 United States Congressional Appropriations Bill A National MS Comprehensive Treatment Training Program Principal Author- $900,000.00


15

2002 United States Congressional Appropriations Bill A National MS Comprehensive Preceptorship Training Program Principal Author- $987,000.00 2003 United States Congressional Appropriations Bill A National MS Comprehensive Preceptorship Training Program Principal Author- $500,000.00 2004 United States Congressional Appropriations Bill A National MS Comprehensive Preceptorship Training Program Principal Author- $950,000.00 2005-present A National MS Comprehensive Preceptorship Training Program Annual funding of $200,000 National MS Society Principal Author and Program Director 2001 Yellow Rose Foundation Research Grant Express Saccades in MS:An Ocular Motor

Neurophysiologic Correlate of Information Processing Speed.

PI-$200,000 (3 years) 2002 National MS Society Neuroradiologic Correlates & Pathophysiology of INO in MS. PI-Pilot Grant-$33,000 2004 National MS Society Thermal regulation of INO in MS Co-PI-Pilot Grant-$39,977 2005 -2007 Once Upon A Time Foundation $250,000 Award for MS Clinical Research 2005 National MS Society Lone Star Chapter Equipment Grant-PI-$50,000 2005 Cain Denius Foundation Award for MS Research PI-$2,000,000


16

2007 National MS Society

MS Training Program PI-$100,000

2007 Viragh Family Foundation MS Center Research Support Neuroimmunology Laboratory Rennovation $200,000 2009 A Validation Study of Diffusion Tensor Imaging As A Measure of Functional Brain Injury Study Sponsor: National MS Society Collaborator/Co-PI with Dr. Bob Fox: $750,000.00 2008/2009 Viragh Family Foundation Modeling MS in the Visual System Collaborative Studies with U Penn, Johns Hopkins Principal Investigator $700,000 2009-2011 National MS Society MS Training Program for Physicians PI-$100,000 2009-2011 National MS Society Research Grant MS Training Program for Nurses and Physician Extenders PI-$100,000 (Gina Remington course Director) 2009 National MS Society Longitudinal MS OCT Study Co-PI-$750,000 2009 National MS Society Research Grant Modeling the pathophysiology of Uhthoff’s phenomenon In MS PI-$185,000 2009 NIH RO1 Research Grant Novel Clinical and Ocular Imaging Outcomes with Long-term

Follow up in MS. Collaborative Consortium Grant with Laura Balcer (U PENN) and Peter Calabresi (Johns Hopkins)

Co-PI-$545,650 2009 Pediatric Eye Research Program


17

Dallas Children’s Hospital Dale Energy Foundation Equipment Grant-$100,000 Proposal Author Co-PI with Benjamin M. Greenberg, MD 2011-2013 The Optic Nerve Head Component in MS Viragh Family Foundation Peer Review Research Grant-$200,000 Proposal and Principal Author/Investigator 2012-2014 Modeling MS Pathophysiology in the Eye Collaborative Grant with UPENN (Balcer)

Johns Hopkins (Calabresi), and UCSF (Green) Dale Energy Family Foundation-$300,000 E.M. Frohman-Principal Investigator/Author

2012 NMSS 4 year 1.1 million grant approved 2012- Ocrelizumab in PPMS PI-UT Southwestern 2012- Ocrelizumab in RRMS PI-UT Southwestern 2013-2014 The Optic Nerve Head Component in MS The Melanopsin Mediated Pupillary Light Reflex as a Surrogate Signature Biomarker For the Retinohypothalamic Tract in MS Viragh Family Foundation Peer Review Research Grant-$200,000 Proposal and Principal Author/Investigator 2014- Viragh Family Foundation Establishment of the Vestibular Neurology and Gait Clinic Equipment Grant- $50,000 2014 Collaborative Research Initiative Dr. Robert Rennaker, Chairman Department of BioEngineering & Computer Science UT Dallas Funding Line to the MS Program: $500,000.00 CLINICAL PROTOCOL PARTICIPATION & GRANT SUPPORT:


18

1996- A double blind, dose escalation study to evaluate the

safety, tolerability and biological activity of 3-every other day intravenous doses of placebo or AG284 (HLA- DR2/MBP84-102) in patients with secondary, chronic progressive multiple sclerosis. Study Sponsor:Anergen.

Principal Investigator 1996-98 A phase I/II trial of safety and immunogenicity of T cell receptor peptide vaccines in patients with multiple sclerosis Study Sponsor:Connective Therapeutics. Principal Investigator 1996- A Natural History Study of INO in MS

Study Sponsor:National MS Society ($206,000) Principal Investigator

199 9 Viagra in Women with MS and Sexual Dysfunction Study Sponsor:Yellow Rose Foundation Principal Investigator 199 9 PROMISE Trial-Copaxone in Primary Progressive MS Study Sponsor:TEVA-Marion Partners Principal Investigator 1999 A Retrospective Review of Interferon b1a in

Secondary Progressive MS. Study Sponsor:Biogen Principal Investigator 1999- A Prospective Randomized Double-Blind Placebo

Controlled Crossover Dosing Clinical Trial of 4-AP In MS Patients with INO Study Sponsor:Acorda Therapeutics

Principal Investigator 2000 Antibiotic therapy for C. pneumoniae infection of the CNS

in MS. In collaboration with Ram Sriram (Vanderbilt) and Jerry Wolinsky (UT Houston)

Study Sponsor:National MS Society 2000 The Oral Copaxone Trial (Coral) Study Sponsor:TEVA-Marion Partners Principal Investigator 2000 A Multi-Center Open Label Antigenicity and Safety Study


19

of Human Serum Albumin-Free Pre-Formulated Solution of Avonex (IFNb1a) administered Intramuscularly to Patient with Relapsing Multiple Sclerosis. Study Sponsor:Biogen Principal Investigator 2002-2004 A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to determine the safety and efficacy of Natalizumab, when added to Avonex in subjects with relapsing-remitting MS (Sentinel). Study Sponsor:Biogen Prinicipal Investigator 2004-2008 A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to determine the safety and efficacy of Natalizumab, when added to Avonex in subjects with relapsing-remitting MS (Sentinel). Open Label Extension Study Study Sponsor:Biogen Prinicipal Investigator 2004 A one-year, prospective, randomized, placebo-controlled,

double-blind, phase II/III safety trial of combination therapy with IFN beta 1a (Avonex) and mycophenolate mofetil

(Cellcept) in early MS Study Sponsor:Biogen and Roche Princiapal Investigator 2004 Factors that influence compliance in disease modifying therapy for MS. Study Sponsor:Biogen Idec Principal Investigator 2005-2009 Cellcept-Avonex Phase II Trial Study Sponsor:Aspreva Principal Investigator and Protocol Author $3,000,000 2005 A Controlled Trial of Tegaserod for the Treatment of Bowel

Dysfunction in MS Study Sponsor:National MS Society/Novartis Principal Investigator $135,000 2006-2007 Memantine for Cognitive Dysfunction in MS


20

Study Sponsor:Forest Principal Investigator $105,000 2007 Accelerated Cure Project Site PI 2008 A Pilot Trial of 4-AP in MS Patients with INO Study Sponsor:National MS Society Principal Investigator $45,000 2008 Neural Control of Skin Blood Flow and Sweating in MS Study Sponsor: National MS Society Co-PI with Dr. Scott Davis $257,154 2008 HALT-Bone Marrow Transplantation in MS

Study Sponsor:NIH and ITN Principal Investigator

2008-present Fingolimod (FTY-720) for PPMS Study Sponsor: Novartis Principal Investigator 2008- National MS Society Research Grant A Validation Study of Diffusion Tensor Imaging as a Physiologically Relevant Biomarker of Brain Tissue Integrity in MS Collaborative 2 Center study with Cleveland Clinic UTSW PI-Percent effort 10% Duration 3 years $750,000 2008 Viragh Family Foundation Research Grant Modeling MS in the Visual System Collaborative Studies with U Penn, Johns Hopkins $700,000 2008- Estriol MS Study Study of Copaxone and Estriol in RRMS SPECIAL ACCOMPLISHMENTS


21

1995 Established the MS Program UT Southwestern Medical Center Currently we follow in excess of 5,000 families 2002-Current Designed the Clincal Center for MS at POB1 I raised funds for the furnishing and equipment costs Served as Director of this Facility since its inception 2010 Designed and raised half of the fundings for the new MS academic and research space on POB 1; 9th floor 1995- My longterm fundraising efforts have been germane to the

building of one of the most prolific MS clinical and research centers in the world today. These efforts have led to many

strategic recruitments of both clinical and research faculty. This funding has also be instrumental in assembling and

retaining one of the most talented multidisciplinary care teams for MS and related disorders anywhere. This team inlcudes physicians, nurses, physician extenders, social workers, technicians, and support staff. Southwestern’s MS Program is widely recognized as among the most successful and significant MS initiatives anywhere.

2001 My authorship of a Congressional Bill led to the

establishment of the first and still sole National MS Treatment Training Program’s in the United States. To date we have trained in excess of 1,000 participants, including about 300 residents (many of whom have gone on to careers in MS and Neuroimmunology).

2011- Establishment of the Total Life Care (TLC) Clinic at UT

Southwestern. This multidisciplinary clinic targets our most afflicted MS patients, with the goal of mitigating morbidity and mortality, while enhancing quality of life. The nurse Director, and co-creator of the TLC, Diana Logan,

recent was the recipient of the Strauss Award at UT Southwestern Medical Center for best nurse.

EDITORIAL POSITIONS:


22

1984-Present Liaison for Medical Affairs The Journal of Mind and Behavior 1987 Associate Editor Inhibition in the brain From a satelite symposium at the 16th annual meeting of the Society of Neuroscience Special issue of the Journal of Mind and Behavior 8(4) 1987 1988 Co-Editor Neuroradiology:Applications in neurology and neurosurgery Special issue of the Journal of Mind and Behavior 8(6) 1988 1990-Present Reviewer-Journal of Neuroimmunology 1996- Reviewer-Journal of Neuro-ophthalmology 1996- Reviewer-Neuro-ophthalmology 1996- Reviewer-Journal of the Neurological Sciences 1998- Reviewer-Annals of Neurology 1998- Book Reviewer-Annals of Neurology 1997- Contributor, US Medical Licensing Exam

National Board of Medical Examiners 2000- Reviewer-Archives of Neurology 2000 Reviewer-Women’s Health in Primary Care 2000- Reviewer-Neurology 2004- Lancet Neurology 2005 Lancet 2012- Brain


23

Publications: 1. Frohman, EM Immunological hit men. UCSD J Undergrad Res. 1980;1:49-51. 2. Frohman, EM, Katz, R. Endorphines and enkephalins:Culprits of pain. UCSD J

Undergrad Res 1982;3:15-18. 3. Frohman, EM. A psycho-neuro-endocrine framework for depression:A clinically

eclectic approach. J Mind Behav 1984;5:151-169. 4. Frohman EM, and van den Noort S. An in vivo assessment of the brain in

Alzheimer's disease. The Western journal of medicine 144: 476, 1986. 5. Frohman EM, and Martin JB. Genetic markers in Huntington's disease. The

Western journal of medicine 147: 486, 1987. 6. Frohman EM, Frohman TC, Vayuvegula B, Gupta S, and van den Noort S.

Vasoactive intestinal polypeptide inhibits the expression of the MHC class II antigens on astrocytes. Journal of the neurological sciences 88: 339-346, 1988.

7. Frohman EM, Vayuvegula B, Gupta S, and van den Noort S. Norepinephrine inhibits gamma-interferon-induced major histocompatibility class II (Ia) antigen expression on cultured astrocytes via beta-2-adrenergic signal transduction mechanisms. Proceedings of the National Academy of Sciences of the United States of America 85: 1292-1296, 1988.

8. Frohman EM, Vayuvegula B, van den Noort S, and Gupta S. Norepinephrine inhibits gamma-interferon-induced MHC class II (Ia) antigen expression on cultured brain astrocytes. Journal of neuroimmunology 17: 89-101, 1988.

9. Frohman EM, Frohman TC, Dustin ML, Vayuvegula B, Choi B, Gupta A, van den Noort S, and Gupta S. The induction of intercellular adhesion molecule 1 (ICAM-1) expression on human fetal astrocytes by interferon-gamma, tumor necrosis factor alpha, lymphotoxin, and interleukin-1: relevance to intracerebral antigen presentation. Journal of neuroimmunology 23: 117-124, 1989.

10. Frohman EM, van den Noort S, and Gupta S. Astrocytes and intracerebral immune responses. Journal of clinical immunology 9: 1-9, 1989.

11. Frohman EM, Frohman TC, Gupta S, de Fougerolles A, and van den Noort S. Expression of intercellular adhesion molecule 1 (ICAM-1) in Alzheimer's disease. Journal of the neurological sciences 106: 105-111, 1991.

12. Ohira K, Vayuvegula B, Murakami M, Gollapudi S, Frohman E, van den Noort S, and Gupta S. Tetraethylammonium, a K+ channel blocker, inhibits interferon-gamma-induced major histocompatibility class II antigen (Ia) expression and DNA synthesis in rat astrocytes. Journal of neuroimmunology 31: 43-49, 1991.

13. Ransohoff RM, Devajyothi C, Estes ML, Babcock G, Rudick RA, Frohman EM, and Barna BP. Interferon-beta specifically inhibits interferon-gamma-induced


24

class II major histocompatibility complex gene transcription in a human astrocytoma cell line. Journal of neuroimmunology 33: 103-112, 1991.

14. Frohman EM, and Zee DS. Ocular neuromyotonia: clinical features, physiological mechanisms, and response to therapy. Annals of neurology 37: 620-626, 1995.

15. Takagi M, Frohman EM, and Zee DS. Gap-overlap effects on latencies of saccades, vergence and combined vergence-saccades in humans. Vision research 35: 3373-3388, 1995.

16. Frohman EM, Tusa R, Mark AS, and Cornblath DR. Vestibular dysfunction in chronic inflammatory demyelinating polyneuropathy. Annals of neurology 39: 529-535, 1996.

17. Togashi H, Sasaki M, Frohman E, Taira E, Ratan RR, Dawson TM, and Dawson VL. Neuronal (type I) nitric oxide synthase regulates nuclear factor kappaB activity and immunologic (type II) nitric oxide synthase expression. Proceedings of the National Academy of Sciences of the United States of America 94: 2676-2680, 1997.

18. Litwiller SE, Frohman EM, and Zimmern PE. Multiple sclerosis and the urologist. The Journal of urology 161: 743-757, 1999.

19. Evans RW, Armon C, Frohman EM, and Goodin DS. Assessment: prevention of post-lumbar puncture headaches: report of the therapeutics and technology assessment subcommittee of the american academy of neurology. Neurology 55: 909-914, 2000.

20. Fife TD, Tusa RJ, Furman JM, Zee DS, Frohman E, Baloh RW, Hain T, Goebel J, Demer J, and Eviatar L. Assessment: vestibular testing techniques in adults and children: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 55: 1431-1441, 2000.

21. Frohman EM, Racke M, and van Den Noort S. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes. Archives of neurology 57: 930-932, 2000.

22. Frohman EM, Zhang H, Dewey RB, Hawker KS, Racke MK, and Frohman TC. Vertigo in MS: utility of positional and particle repositioning maneuvers. Neurology 55: 1566-1569, 2000.

23. Goodkin DE, Shulman M, Winkelhake J, Waubant E, Andersson P, Stewart T, Nelson S, Fischbein N, Coyle PK, Frohman E, Jacobs L, Holcenberg J, Lee M, and Mocci S. A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis. Neurology 54: 1414-1420, 2000.

24. Frohman EM, Frohman TC, Fleckenstein J, Racke MK, Hawker K, and Kramer PD. Ocular contrapulsion in multiple sclerosis: clinical features and


25

pathophysiological mechanisms. Journal of neurology, neurosurgery, and psychiatry 70: 688-692, 2001.

25. Frohman EM, Monson NL, Lovett-Racke AE, and Racke MK. Autonomic regulation of neuroimmunological responses: implications for multiple sclerosis. Journal of clinical immunology 21: 61-73, 2001.

26. Frohman EM, Zhang H, Kramer PD, Fleckenstein J, Hawker K, Racke MK, and Frohman TC. MRI characteristics of the MLF in MS patients with chronic internuclear ophthalmoparesis. Neurology 57: 762-768, 2001.

27. Hawker KS, and Frohman EM. Bladder, Bowel, and Sexual Dysfunction in Multiple Sclerosis. Current treatment options in neurology 3: 207-214, 2001.

28. Lewis JB, Jr., and Frohman EM. Diagnosis and management of headache. Obstetrics and gynecology clinics of North America 28: 205-224, v, 2001.

29. Racke MK, Hawker K, and Frohman EM. Multiple sclerosis and magnetic resonance imaging: advancement in linking the pictures with the progression. Archives of neurology 58: 35-36, 2001.

30. Frohman E, Phillips T, Kokel K, Van Pelt J, O'Leary S, Gross S, Hawker K, and Racke M. Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. The neurologist 8: 227-236, 2002.

31. Frohman EM. Sexual dysfunction in neurologic disease. Clinical neuropharmacology 25: 126-132, 2002.

32. Frohman EM, Frohman TC, and Moreault AM. Acquired sexual paraphilia in patients with multiple sclerosis. Archives of neurology 59: 1006-1010, 2002.

33. Frohman EM, Frohman TC, O'Suilleabhain P, Zhang H, Hawker K, Racke MK, Frawley W, Phillips JT, and Kramer PD. Quantitative oculographic characterisation of internuclear ophthalmoparesis in multiple sclerosis: the versional dysconjugacy index Z score. Journal of neurology, neurosurgery, and psychiatry 73: 51-55, 2002.

34. Goodin DS, Frohman EM, Garmany GP, Jr., Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, and van den Noort S. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58: 169-178, 2002.

35. Karandikar NJ, Crawford MP, Yan X, Ratts RB, Brenchley JM, Ambrozak DR, Lovett-Racke AE, Frohman EM, Stastny P, Douek DC, Koup RA, and Racke MK. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. The Journal of clinical investigation 109: 641-649, 2002.


26

36. Kramer P, Frohman EM, Nuti D, and Zee DS. The effects of horizontal head position (yaw axis) and step velocity on the vestibulo-ocular reflex. Annals of the New York Academy of Sciences 956: 530-532, 2002.

37. Corboy JR, Goodin DS, and Frohman EM. Disease-modifying Therapies for Multiple Sclerosis. Current treatment options in neurology 5: 35-54, 2003.

38. De Keyser J, Zeinstra E, and Frohman E. Are astrocytes central players in the pathophysiology of multiple sclerosis? Archives of neurology 60: 132-136, 2003.

39. Frohman EM. Multiple sclerosis. The Medical clinics of North America 87: 867-897, viii-ix, 2003.

40. Frohman EM, and Frohman TC. Horizontal monocular saccadic failure: an unusual clinically isolated syndrome progressing to multiple sclerosis. Mult Scler 9: 55-58, 2003.

41. Frohman EM, Goodin DS, Calabresi PA, Corboy JR, Coyle PK, Filippi M, Frank JA, Galetta SL, Grossman RI, Hawker K, Kachuck NJ, Levin MC, Phillips JT, Racke MK, Rivera VM, and Stuart WH. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 61: 602-611, 2003.

42. Frohman EM, Kramer PD, Dewey RB, Kramer L, and Frohman TC. Benign paroxysmal positioning vertigo in multiple sclerosis: diagnosis, pathophysiology and therapeutic techniques. Mult Scler 9: 250-255, 2003.

43. Frohman EM, O'Suilleabhain P, Dewey RB, Jr., Frohman TC, and Kramer PD. A new measure of dysconjugacy in INO: the first-pass amplitude. Journal of the neurological sciences 210: 65-71, 2003.

44. Frohman TC, Frohman EM, O'Suilleabhain P, Salter A, Dewey RB, Jr., Hogan N, Galetta S, Lee AG, Straumann D, Noseworthy J, Zee D, Corbett J, Corboy J, Rivera VM, and Kramer PD. Accuracy of clinical detection of INO in MS: corroboration with quantitative infrared oculography. Neurology 61: 848-850, 2003.

45. Goodin DS, Arnason BG, Coyle PK, Frohman EM, and Paty DW. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 61: 1332-1338, 2003.

46. Hawker K, Frohman E, and Racke M. Levetiracetam for phasic spasticity in multiple sclerosis. Archives of neurology 60: 1772-1774, 2003.

47. Shy ME, Frohman EM, So YT, Arezzo JC, Cornblath DR, Giuliani MJ, Kincaid JC, Ochoa JL, Parry GJ, and Weimer LH. Quantitative sensory testing: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 60: 898-904, 2003.


27

48. Chen CJ, Scheufele M, Sheth M, Torabi A, Hogan N, and Frohman EM. Isolated relative afferent pupillary defect secondary to contralateral midbrain compression. Archives of neurology 61: 1451-1453, 2004.

49. Frohman EM, Brannon K, Alexander S, Sims D, Phillips JT, O'Leary S, Hawker K, and Racke MK. Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management. Mult Scler 10: 302-307, 2004.

50. Frohman EM, Brannon K, Racke MK, and Hawker K. Mycophenolate mofetil in multiple sclerosis. Clinical neuropharmacology 27: 80-83, 2004.

51. Frohman EM, Dewey RB, and Frohman TC. An unusual variant of the dorsal midbrain syndrome in MS: clinical characteristics and pathophysiologic mechanisms. Mult Scler 10: 322-325, 2004.

52. Hawker K, and Frohman E. Multiple sclerosis. Primary care 31: 201-226, 2004. 53. Kumar N, and Frohman EM. Spinal neurosarcoidosis mimicking an idiopathic

inflammatory demyelinating syndrome. Archives of neurology 61: 586-589, 2004. 54. Phillips JT, Rice G, Frohman E, Vande Gaer L, Scott T, Haas J, Eggenberger E,

Freedman MS, Stuart W, Cunha L, Jacobs L, Oger J, Arnold D, Murray TJ, DiBiase M, Jethwa V, and Goelz S. A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. Clinical therapeutics 26: 511-521, 2004.

55. Racke MK, Hawker K, and Frohman EM. Fatigue in multiple sclerosis: is the picture getting simpler or more complex? Archives of neurology 61: 176-177, 2004.

56. Frohman EM, Filippi M, Stuve O, Waxman SG, Corboy J, Phillips JT, Lucchinetti C, Wilken J, Karandikar N, Hemmer B, Monson N, De Keyser J, Hartung H, Steinman L, Oksenberg JR, Cree BA, Hauser S, and Racke MK. Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Archives of neurology 62: 1345-1356, 2005.

57. Frohman EM, Frohman TC, Zee DS, McColl R, and Galetta S. The neuro-ophthalmology of multiple sclerosis. Lancet neurology 4: 111-121, 2005.

58. Frohman EM, Stuve O, Havrdova E, Corboy J, Achiron A, Zivadinov R, Sorensen PS, Phillips JT, Weinshenker B, Hawker K, Hartung HP, Steinman L, Zamvil S, Cree BA, Hauser S, Weiner H, Racke MK, and Filippi M. Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. Archives of neurology 62: 1519-1530, 2005.

59. Lemack GE, Hawker K, and Frohman E. Incidence of upper tract abnormalities in patients with neurovesical dysfunction secondary to multiple sclerosis: analysis of risk factors at initial urologic evaluation. Urology 65: 854-857, 2005.


28

60. Monson NL, Brezinschek HP, Brezinschek RI, Mobley A, Vaughan GK, Frohman EM, Racke MK, and Lipsky PE. Receptor revision and atypical mutational characteristics in clonally expanded B cells from the cerebrospinal fluid of recently diagnosed multiple sclerosis patients. Journal of neuroimmunology 158: 170-181, 2005.

61. Monson NL, Cravens PD, Frohman EM, Hawker K, and Racke MK. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Archives of neurology 62: 258-264, 2005.

62. Filippi M, Rocca MA, Arnold DL, Bakshi R, Barkhof F, De Stefano N, Fazekas F, Frohman E, and Wolinsky JS. EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. European journal of neurology : the official journal of the European Federation of Neurological Societies 13: 313-325, 2006.

63. Fisher JB, Jacobs DA, Markowitz CE, Galetta SL, Volpe NJ, Nano-Schiavi ML, Baier ML, Frohman EM, Winslow H, Frohman TC, Calabresi PA, Maguire MG, Cutter GR, and Balcer LJ. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 113: 324-332, 2006.

64. Frohman E, Costello F, Zivadinov R, Stuve O, Conger A, Winslow H, Trip A, Frohman T, and Balcer L. Optical coherence tomography in multiple sclerosis. Lancet neurology 5: 853-863, 2006.

65. Frohman EM, Havrdova E, Levinson B, and Slanar O. Azathioprine myelosuppression in multiple sclerosis: characterizing thiopurine methyltransferase polymorphisms. Mult Scler 12: 108-111, 2006.

66. Frohman EM, Havrdova E, Lublin F, Barkhof F, Achiron A, Sharief MK, Stuve O, Racke MK, Steinman L, Weiner H, Olek M, Zivadinov R, Corboy J, Raine C, Cutter G, Richert J, and Filippi M. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Archives of neurology 63: 614-619, 2006.

67. Frohman EM, Racke MK, and Raine CS. Multiple sclerosis--the plaque and its pathogenesis. The New England journal of medicine 354: 942-955, 2006.

68. Goodin DS, and Frohman EM. Overdiagnosis of multiple sclerosis by magnetic resonance imaging. Annals of neurology 59: 575-576; author reply 576, 2006.

69. Hemmer B, Frohman E, Hartung HP, and Stuve O. Central nervous system infections - a potential complication of systemic immunotherapy. Current opinion in neurology 19: 271-276, 2006.

70. Lemack GE, Frohman EM, Zimmern PE, Hawker K, and Ramnarayan P. Urodynamic distinctions between idiopathic detrusor overactivity and detrusor overactivity secondary to multiple sclerosis. Urology 67: 960-964, 2006.

71. Stuve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Jerome KR, Cook L, Grand'Maison F, Hemmer B, Monson NL, and Racke MK. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of


29

natalizumab-treated patients with multiple sclerosis. Archives of neurology 63: 1383-1387, 2006.

72. Stuve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Hemmer B, Monson NL, and Racke MK. Immune surveillance in multiple sclerosis patients treated with natalizumab. Annals of neurology 59: 743-747, 2006.

73. Winslow H, Mickey B, and Frohman EM. Sympathomimetic-induced kaleidoscopic visual illusion associated with a reversible splenium lesion. Archives of neurology 63: 135-137, 2006.

74. Woo DA, Olek MJ, and Frohman EM. Diagnosis and management of multiple sclerosis: case studies. Neurologic clinics 24: 199-214, 2006.

75. Costello F, Stuve O, Weber MS, Zamvil SS, and Frohman E. Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice. Current opinion in neurology 20: 281-285, 2007.

76. Frohman EM, and Kerr D. Is neuromyelitis optica distinct from multiple sclerosis?: something for "lumpers" and "splitters". Archives of neurology 64: 903-905, 2007.

77. Frohman EM, Shah A, Eggenberger E, Metz L, Zivadinov R, and Stuve O. Corticosteroids for multiple sclerosis: I. Application for treating exacerbations. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 4: 618-626, 2007.

78. Shah A, Eggenberger E, Zivadinov R, Stuve O, and Frohman EM. Corticosteroids for multiple sclerosis: II. Application for disease-modifying effects. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 4: 627-632, 2007.

79. Frohman EM, and Zivadinov R. What you see is what you get: coupling function with structure in the visual system. Neurology 69: 2119-2120, 2007.

80. Goodin DS, Frohman EM, Hurwitz B, O'Connor PW, Oger JJ, Reder AT, and Stevens JC. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 68: 977-984, 2007.

81. Gordon-Lipkin E, Chodkowski B, Reich DS, Smith SA, Pulicken M, Balcer LJ, Frohman EM, Cutter G, and Calabresi PA. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology 69: 1603-1609, 2007.

82. Harp C, Lee J, Lambracht-Washington D, Cameron E, Olsen G, Frohman E, Racke M, and Monson N. Cerebrospinal fluid B cells from multiple sclerosis patients are subject to normal germinal center selection. Journal of neuroimmunology 183: 189-199, 2007.


30

83. Lambracht-Washington D, O'Connor KC, Cameron EM, Jowdry A, Ward ES, Frohman E, Racke MK, and Monson NL. Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MS. Journal of neuroimmunology 186: 164-176, 2007.

84. Lemack GE, Frohman E, and Ramnarayan P. Women with voiding dysfunction secondary to bladder outlet dyssynergia in the setting of multiple sclerosis do not demonstrate significantly elevated intravesical pressures. Urology 69: 893-897, 2007.

85. Pulicken M, Gordon-Lipkin E, Balcer LJ, Frohman E, Cutter G, and Calabresi PA. Optical coherence tomography and disease subtype in multiple sclerosis. Neurology 69: 2085-2092, 2007.

86. Sergott RC, Frohman E, Glanzman R, and Al-Sabbagh A. The role of optical coherence tomography in multiple sclerosis: expert panel consensus. Journal of the neurological sciences 263: 3-14, 2007.

87. Frohman EM, Stuve O, and Miller DH. W. Ian McDonald, MB, ChB, PhD (1933-2006): the multiple sclerosis physician-scientist of the 20th century. Archives of neurology 64: 452-454, 2007.

88. Stuart R, Lovett-Racke AE, Frohman EM, Hawker K, and Racke MK. Genetic analysis of the exon 1 position 49 CD152 dimorphism in multiple sclerosis. Journal of neuroimmunology 191: 45-50, 2007.

89. Stuve O, Cravens PD, Singh MP, Frohman EM, Phillips JT, Remington G, Hu W, Hemmer B, Olek MJ, Monson NL, and Racke MK. High incidence of post-lumbar puncture headaches in patients with multiple sclerosis treated with natalizumab: role of intrathecal leukocytes. Archives of neurology 64: 1055-1056, 2007.

90. Stuve O, Eagar TN, Frohman EM, and Cravens PD. DNA plasmid vaccination for multiple sclerosis. Archives of neurology 64: 1385-1386, 2007.

91. Stuve O, Marra CM, Cravens PD, Singh MP, Hu W, Lovett-Racke A, Monson NL, Phillips JT, Tervaert JW, Nash RA, Hartung HP, Kieseier BC, Racke MM, Frohman EM, and Hemmer B. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Archives of neurology 64: 169-176, 2007.

92. Watson NF, Woo D, Doherty MJ, Frohman EM, Racke MK, De Baets M, Hartung HP, Kieseier BC, and Stuve O. Humoral immune responses after rabies infection. Archives of neurology 64: 1355-1356, 2007.

93. Boster A, Edan G, Frohman E, Javed A, Stuve O, Tselis A, Weiner H, Weinstock-Guttman B, and Khan O. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet neurology 7: 173-183, 2008.

94. Cettomai D, Pulicken M, Gordon-Lipkin E, Salter A, Frohman TC, Conger A, Zhang X, Cutter G, Balcer LJ, Frohman EM, and Calabresi PA. Reproducibility of


31

optical coherence tomography in multiple sclerosis. Archives of neurology 65: 1218-1222, 2008.

95. Davis SL, Frohman TC, Crandall CG, Brown MJ, Mills DA, Kramer PD, Stuve O, and Frohman EM. Modeling Uhthoff's phenomenon in MS patients with internuclear ophthalmoparesis. Neurology 70: 1098-1106, 2008.

96. del Pilar Martin M, Cravens PD, Winger R, Frohman EM, Racke MK, Eagar TN, Zamvil SS, Weber MS, Hemmer B, Karandikar NJ, Kleinschmidt-DeMasters BK, and Stuve O. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Archives of neurology 65: 1596-1603, 2008.

97. Fox RJ, McColl RW, Lee JC, Frohman T, Sakaie K, and Frohman E. A preliminary validation study of diffusion tensor imaging as a measure of functional brain injury. Archives of neurology 65: 1179-1184, 2008.

98. Frohman EM, Costello F, Stuve O, Calabresi P, Miller DH, Hickman SJ, Sergott R, Conger A, Salter A, Krumwiede KH, Frohman TC, Balcer L, and Zivadinov R. Modeling axonal degeneration within the anterior visual system: implications for demonstrating neuroprotection in multiple sclerosis. Archives of neurology 65: 26-35, 2008.

99. Frohman EM, Eagar T, Monson N, Stuve O, and Karandikar N. Immunologic mechanisms of multiple sclerosis. Neuroimaging clinics of North America 18: 577-588, ix, 2008.

100. Frohman EM, Fujimoto JG, Frohman TC, Calabresi PA, Cutter G, and Balcer LJ. Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nature clinical practice Neurology 4: 664-675, 2008.

101. Frohman TC, Galetta S, Fox R, Solomon D, Straumann D, Filippi M, Zee D, and Frohman EM. Pearls & Oy-sters: The medial longitudinal fasciculus in ocular motor physiology. Neurology 70: e57-67, 2008.

102. Harp CT, Lovett-Racke AE, Racke MK, Frohman EM, and Monson NL. Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis. Clin Immunol 128: 382-391, 2008.

103. Hu W, Kieseier B, Frohman E, Eagar TN, Rosenberg RN, Hartung HP, and Stuve O. Prion proteins: physiological functions and role in neurological disorders. Journal of the neurological sciences 264: 1-8, 2008.

104. Mills DA, Frohman TC, Davis SL, Salter AR, McClure S, Beatty I, Shah A, Galetta S, Eggenberger E, Zee DS, and Frohman EM. Break in binocular fusion during head turning in MS patients with INO. Neurology 71: 458-460, 2008.

105. Nash RA, Stuve O, Bowen JD, Frohman EM, Griffith LM, Hutton GJ, Kraft GH, Popat U, Racke MK, and Muraro PA. Autologous HSCT for advanced MS: is the glass half-empty or really half-full? Brain : a journal of neurology 131: e89; author reply e90, 2008.


32

106. Phillips JT, and Frohman EM. Natalizumab: benefit outweighs risk in selected patients with multiple sclerosis. Therapeutic advances in neurological disorders 1: 151-153, 2008.

107. Stuve O, Bennett JL, Hemmer B, Wiendl H, Racke MK, Bar-Or A, Hu W, Zivadinov R, Weber MS, Zamvil SS, Pacheco MF, Menge T, Hartung HP, Kieseier BC, and Frohman EM. Pharmacological treatment of early multiple sclerosis. Drugs 68: 73-83, 2008.

108. Villoslada P, Sepulcre J, Toledo J, and Bejarano B. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology 71: 1747; author reply 1747-1748, 2008.

109. Yao K, Gagnon S, Akhyani N, Williams E, Fotheringham J, Frohman E, Stuve O, Monson N, Racke MK, and Jacobson S. Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients. PloS one 3: e2028, 2008.

110. Zaveri MS, Conger A, Salter A, Frohman TC, Galetta SL, Markowitz CE, Jacobs DA, Cutter GR, Ying GS, Maguire MG, Calabresi PA, Balcer LJ, and Frohman EM. Retinal imaging by laser polarimetry and optical coherence tomography evidence of axonal degeneration in multiple sclerosis. Archives of neurology 65: 924-928, 2008.

111. Zivadinov R, Reder AT, Filippi M, Minagar A, Stuve O, Lassmann H, Racke MK, Dwyer MG, Frohman EM, and Khan O. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 71: 136-144, 2008.

112. Beeravolu LR, Frohman EM, Frohman TC, Remington GM, Lee S, and Levin MC. Pearls & Oy-sters: "Not multiple sclerosis" and the changing face of HTLV-1: A case report of downbeat nystagmus. Neurology 72: e119-120, 2009.

113. Burkholder BM, Osborne B, Loguidice MJ, Bisker E, Frohman TC, Conger A, Ratchford JN, Warner C, Markowitz CE, Jacobs DA, Galetta SL, Cutter GR, Maguire MG, Calabresi PA, Balcer LJ, and Frohman EM. Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis. Archives of neurology 66: 1366-1372, 2009.

114. Cameron EM, Spencer S, Lazarini J, Harp CT, Ward ES, Burgoon M, Owens GP, Racke MK, Bennett JL, Frohman EM, and Monson NL. Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis. Journal of neuroimmunology 213: 123-130, 2009.

115. Courtney AM, Treadaway K, Remington G, and Frohman E. Multiple sclerosis. The Medical clinics of North America 93: 451-476, ix-x, 2009.

116. Fletcher SG, Castro-Borrero W, Remington G, Treadaway K, Lemack GE, and Frohman EM. Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and management. Nature clinical practice Urology 6: 96-107, 2009.


33

117. Frohman EM, Dwyer MG, Frohman T, Cox JL, Salter A, Greenberg BM, Hussein S, Conger A, Calabresi P, Balcer LJ, and Zivadinov R. Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: a pilot study. Journal of the neurological sciences 282: 96-105, 2009.

118. Hu W, Metselaar J, Ben LH, Cravens PD, Singh MP, Frohman EM, Eagar TN, Racke MK, Kieseier BC, and Stuve O. PEG minocycline-liposomes ameliorate CNS autoimmune disease. PloS one 4: e4151, 2009.

119. Hussain RZ, Hopkins SC, Frohman EM, Eagar TN, Cravens PC, Greenberg BM, Vernino S, and Stuve O. Direct and consensual murine pupillary reflex metrics: establishing normative values. Autonomic neuroscience : basic & clinical 151: 164-167, 2009.

120. Martin Mdel P, Cravens PD, Winger R, Kieseier BC, Cepok S, Eagar TN, Zamvil SS, Weber MS, Frohman EM, Kleinschmidt-Demasters BK, Montine TJ, Hemmer B, Marra CM, and Stuve O. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Archives of neurology 66: 1016-1020, 2009.

121. Ratchford JN, Quigg ME, Conger A, Frohman T, Frohman E, Balcer LJ, Calabresi PA, and Kerr DA. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology 73: 302-308, 2009.

122. Salter AR, Conger A, Frohman TC, Zivadinov R, Eggenberger E, Calabresi P, Cutter G, Balcer L, and Frohman EM. Retinal architecture predicts pupillary reflex metrics in MS. Mult Scler 15: 479-486, 2009.

123. Stuve O, Cravens PD, Frohman EM, Phillips JT, Remington GM, von Geldern G, Cepok S, Singh MP, Tervaert JW, De Baets M, MacManus D, Miller DH, Radu EW, Cameron EM, Monson NL, Zhang S, Kim R, Hemmer B, and Racke MK. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 72: 396-401, 2009.

124. Stuve O, Korth C, Gabatto P, Cameron EM, Hu W, Eagar TN, Monson NL, Frohman EM, Racke MK, Zabetian CP, and Oksenberg JR. Genetic polymorphism at codon 129 of the prion protein gene is not associated with multiple sclerosis. Archives of neurology 66: 280-281, 2009.

125. Treadaway K, Cutter G, Salter A, Lynch S, Simsarian J, Corboy J, Jeffery D, Cohen B, Mankowski K, Guarnaccia J, Schaeffer L, Kanter R, Brandes D, Kaufman C, Duncan D, Marder E, Allen A, Harney J, Cooper J, Woo D, Stuve O, Racke M, and Frohman EM. Factors that influence adherence with disease-modifying therapy in MS. Journal of neurology 256: 568-576, 2009.

126. Balcer LJ, and Frohman EM. Evaluating loss of visual function in multiple sclerosis as measured by low-contrast letter acuity. Neurology 74 Suppl 3: S16-23, 2010.


34

127. Calabresi PA, Balcer LJ, and Frohman EM. Retinal pathology in multiple sclerosis: insight into the mechanisms of neuronal pathology. Brain : a journal of neurology 133: 1575-1577, 2010.

128. Cettomai D, Hiremath G, Ratchford J, Venkatesan A, Greenberg BM, McGready J, Pardo CA, Kerr DA, Frohman E, Balcer LJ, McArthur JC, and Calabresi PA. Associations between retinal nerve fiber layer abnormalities and optic nerve examination. Neurology 75: 1318-1325, 2010.

129. Davis SL, Wilson TE, White AT, and Frohman EM. Thermoregulation in multiple sclerosis. J Appl Physiol 109: 1531-1537, 2010.

130. Frohman EM, Balcer LJ, and Calabresi PA. Multiple sclerosis: can retinal imaging accurately detect optic neuritis? Nature reviews Neurology 6: 125-126, 2010.

131. Frohman EM, Cutter G, Remington G, Gao H, Rossman H, Weinstock-Guttman B, Durfee JE, Conger A, Carl E, Treadaway K, Lindzen E, Salter A, Frohman TC, Shah A, Bates A, Cox JL, Dwyer MG, Stuve O, Greenberg BM, Racke MK, and Zivadinov R. A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. Therapeutic advances in neurological disorders 3: 15-28, 2010.

132. Remington GM, Treadaway K, Frohman T, Salter A, Stuve O, Racke MK, Hawker K, Agosta F, Sormani MP, Filippi M, and Frohman EM. A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS). Therapeutic advances in neurological disorders 3: 3-13, 2010.

133. Frohman EM, and Wingerchuk DM. Clinical practice. Transverse myelitis. New Engl J Med 363: 564-572, 2010.

134. Frohman TC, Graves J, Balcer LJ, Galetta SL, and Frohman EM. The neuro-ophthalmology of multiple sclerosis. Continuum (Minneap Minn) 16: 122-146, 2010.

135. Greenberg BM, and Frohman E. Optical coherence tomography as a potential readout in clinical trials. Therapeutic advances in neurological disorders 3: 153-160, 2010.

136. Harp CT, Ireland S, Davis LS, Remington G, Cassidy B, Cravens PD, Stuve O, Lovett-Racke AE, Eagar TN, Greenberg BM, Racke MK, Cowell LG, Karandikar NJ, Frohman EM, and Monson NL. Memory B cells from a subset of treatment-naive relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-gamma production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. European journal of immunology 40: 2942-2956, 2010.


35

137. Ligocki AJ, Lovato L, Xiang D, Guidry P, Scheuermann RH, Willis SN, Almendinger S, Racke MK, Frohman EM, Hafler DA, O'Connor KC, and Monson NL. A unique antibody gene signature is prevalent in the central nervous system of patients with multiple sclerosis. Journal of neuroimmunology 226: 192-193, 2010.

138. Lovera JF, Frohman E, Brown TR, Bandari D, Nguyen L, Yadav V, Stuve O, Karman J, Bogardus K, Heimburger G, Cua L, Remingon G, Fowler J, Monahan T, Kilcup S, Courtney Y, McAleenan J, Butler K, Wild K, Whitham R, and Bourdette D. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Mult Scler 16: 715-723, 2010.

139. Stuve O, Kieseier BC, Hemmer B, Hartung HP, Awad A, Frohman EM, Greenberg BM, Racke MK, Zamvil SS, Phillips JT, Gold R, Chan A, Zettl U, Milo R, Marder E, Khan O, and Eagar TN. Translational research in neurology and neuroscience 2010: multiple sclerosis. Archives of neurology 67: 1307-1315, 2010.

140. Frohman EM, and Greenberg BM. Pearls: multiple sclerosis. Seminars in neurology 30: 97-101, 2010.

141. Syc SB, Warner CV, Hiremath GS, Farrell SK, Ratchford JN, Conger A, Frohman T, Cutter G, Balcer LJ, Frohman EM, and Calabresi PA. Reproducibility of high-resolution optical coherence tomography in multiple sclerosis. Mult Scler 16: 829-839, 2010.

142. Talman LS, Bisker ER, Sackel DJ, Long DA, Jr., Galetta KM, Ratchford JN, Lile DJ, Farrell SK, Loguidice MJ, Remington G, Conger A, Frohman TC, Jacobs DA, Markowitz CE, Cutter GR, Ying GS, Dai Y, Maguire MG, Galetta SL, Frohman EM, Calabresi PA, and Balcer LJ. Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Annals of Neurology 67: 749-760, 2010.

143. Warnke C, Menge T, Hartung HP, Racke MK, Cravens PD, Bennett JL, Frohman EM, Greenberg BM, Zamvil SS, Gold R, Hemmer B, Kieseier BC, and Stuve O. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Archives of neurology 67: 923-930, 2010.

144. Baughman EJ, Mendoza JP, Ortega SB, Ayers CL, Greenberg BM, Frohman EM, and Karandikar NJ. Neuroantigen-specific CD8+ regulatory T-cell function is deficient during acute exacerbation of multiple sclerosis. Journal of autoimmunity 36: 115-124, 2011.

145. Burton EV, Greenberg BM, and Frohman EM. Optic neuritis: A mechanistic view. Pathophysiology : the official journal of the International Society for Pathophysiology / ISP 18: 81-92, 2011.

146. Courtney AM, Castro-Borrero W, Davis SL, Frohman TC, and Frohman EM. Functional treatments in multiple sclerosis. Current opinion in neurology 24: 250-254, 2011.


36

147. Davies EC, Galetta KM, Sackel DJ, Talman LS, Frohman EM, Calabresi PA, Galetta SL, and Balcer LJ. Retinal ganglion cell layer volumetric assessment by spectral-domain optical coherence tomography in multiple sclerosis: application of a high-precision manual estimation technique. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 31: 260-264, 2011.

148. Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P, Suchet L, Hyde R, Balla I, Frohman EM, and Kieseier BC. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. European journal of neurology : the official journal of the European Federation of Neurological Societies 18: 69-77, 2011.

149. Waldman AT, Gorman MP, Rensel MR, Austin TE, Hertz DP, Kuntz NL; Network of Pediatric Multiple Sclerosis Centers of Excellence of National Multiple Sclerosis Society. Management of pediatric central nervous system demyelinating disorders: consensus of United States neurologists. J Child Neurol. 2011 Jun;26(6):675-82.

150. Frohman TC, Castro W, Shah A, Courtney A, Ortstadt J, Davis SL, Logan D, Abraham T, Abraham J, Remington G, Treadaway K, Graves D, Hart J, Stuve O, Lemack G, Greenberg B, and Frohman EM. Symptomatic therapy in multiple sclerosis. Therapeutic advances in neurological disorders 4: 83-98, 2011.

151. Frohman TC, Davis SL, and Frohman EM. Modeling the mechanisms of Uhthoff's phenomenon in MS patients with internuclear ophthalmoparesis. Annals of the New York Academy of Sciences 1233: 313-319, 2011.

152. Galetta KM, Calabresi PA, Frohman EM, and Balcer LJ. Optical coherence tomography (OCT): imaging the visual pathway as a model for neurodegeneration. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 8: 117-132, 2011.

153. Marder E, Gupta P, Greenberg BM, Frohman EM, Awad AM, Bagert B, and Stuve O. No cerebral or cervical venous insufficiency in US veterans with multiple sclerosis. Archives of neurology 68: 1521-1525, 2011.

154. Pineles SL, Birch EE, Talman LS, Sackel DJ, Frohman EM, Calabresi PA, Galetta SL, Maguire MG, and Balcer LJ. One eye or two: a comparison of binocular and monocular low-contrast acuity testing in multiple sclerosis. American journal of ophthalmology 152: 133-140, 2011.

155. Sadowsky CL, Becker D, Bosques G, Dean JM, McDonald JW, 3rd, Recio A, and Frohman EM. Rehabilitation in transverse myelitis. Continuum (Minneap Minn) 17: 816-830, 2011.

156. Saidha S, Syc SB, Durbin MK, Eckstein C, Oakley JD, Meyer SA, Conger A, Frohman TC, Newsome S, Ratchford JN, Frohman EM, and Calabresi PA. Visual dysfunction in multiple sclerosis correlates better with optical coherence


37

tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness. Mult Scler 17: 1449-1463, 2011.

157. Saidha S, Syc SB, Ibrahim MA, Eckstein C, Warner CV, Farrell SK, Oakley JD, Durbin MK, Meyer SA, Balcer LJ, Frohman EM, Rosenzweig JM, Newsome SD, Ratchford JN, Nguyen QD, and Calabresi PA. Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain 134: 518-533, 2011.

158. Sakaie K, Takahashi M, Dimitrov I, Togao O, Davis S, Remington G, Conger A, Conger D, Frohman T, Fox R, and Frohman E. Diffusion tensor imaging the medial longitudinal fasciculus in INO: opportunities and challenges. Annals of the New York Academy of Sciences 1233: 307-312, 2011.

159. Scott TF, Frohman EM, De Seze J, Gronseth GS, and Weinshenker BG. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 77: 2128-2134, 2011.

160. Syc SB, Warner CV, Saidha S, Farrell SK, Conger A, Bisker ER, Wilson J, Frohman TC, Frohman EM, Balcer LJ, and Calabresi PA. Cup to disc ratio by optical coherence tomography is abnormal in multiple sclerosis. Journal of the neurological sciences 302: 19-24, 2011.

161. Warner CV, Syc SB, Stankiewicz AM, Hiremath G, Farrell SK, Crainiceanu CM, Conger A, Frohman TC, Bisker ER, Balcer LJ, Frohman EM, Calabresi PA, and Saidha S. The impact of utilizing different optical coherence tomography devices for clinical purposes and in multiple sclerosis trials. PloS one 6: e22947, 2011.

162. Beh SC, and Frohman EM. WEBINO and the return of the King's Speech. Journal of the neurological sciences 315: 153-155, 2012.

163. Blazek P, Davis SL, Greenberg BM, Conger A, Conger D, Vernino S, Beh S, Stuve O, Saidha S, Ratchford JN, Green A, Calabresi PA, Balcer LJ, Frohman TC, and Frohman EM. Objective characterization of the relative afferent pupillary defect in MS. Journal of the neurological sciences 323: 193-200, 2012.

164. Bomprezzi R, Okuda DT, Alderazi YJ, Stuve O, and Frohman EM. From injection therapies to natalizumab: views on the treatment of multiple sclerosis. Therapeutic advances in neurological disorders 5: 97-104, 2012.

165. Castro-Borrero W, Graves D, Frohman TC, Flores AB, Hardeman P, Logan D, Orchard M, Greenberg B, and Frohman EM. Current and emerging therapies in multiple sclerosis: a systematic review. Therapeutic advances in neurological disorders 5: 205-220, 2012.

166. Dillon BE, Seideman CA, Lee D, Greenberg B, Frohman EM, and Lemack GE. A Surprisingly Low Prevalence of Demonstrable Stress Urinary Incontinence and Pelvic Organ Prolapse in Women with Multiple Sclerosis Followed at a Tertiary Neurogenic Bladder Clinic. The Journal of urology 2012.


38

167. Frohman AR, Schnurman Z, Conger A, Conger D, Beh S, Greenberg B, Sutter E, Calabresi PA, Balcer LJ, Frohman TC, and Frohman EM. Multifocal visual evoked potentials are influenced by variable contrast stimulation in MS. Neurology 79: 797-801, 2012.

168. Galetta KM, Graves J, Talman LS, Lile DJ, Frohman EM, Calabresi PA, Galetta SL, and Balcer LJ. Visual pathway axonal loss in benign multiple sclerosis: a longitudinal study. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 32: 116-123, 2012.

169. Greenberg BM, Balcer L, Calabresi PA, Cree B, Cross A, Frohman T, Gold R, Havrdova E, Hemmer B, Kieseier BC, Lisak R, Miller A, Racke MK, Steinman L, Stuve O, Wiendl H, and Frohman E. Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis. Archives of neurology 1-4, 2012.

170. Greenberg BM, Graves D, Remington G, Hardeman P, Mann M, Karandikar N, Stuve O, Monson N, and Frohman E. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler 18: 1022-1026, 2012.

171. Harder LL, Holland AA, Frohman E, Graves D, and Greenberg BM. Cognitive functioning in pediatric transverse myelitis. Mult Scler 2012.

172. Ireland SJ, Blazek M, Harp CT, Greenberg B, Frohman EM, Davis LS, and Monson NL. Antibody-independent B cell effector functions in relapsing remitting multiple sclerosis: clues to increased inflammatory and reduced regulatory B cell capacity. Autoimmunity 45: 400-414, 2012.

173. Perkins MR, Ryschkewitsch C, Liebner JC, Monaco MC, Himelfarb D, Ireland S, Roque A, Edward HL, Jensen PN, Remington G, Abraham T, Abraham J, Greenberg B, Kaufman C, LaGanke C, Monson NL, Xu X, Frohman E, Major EO, and Douek DC. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy. PLoS pathogens 8: e1003014, 2012.

174. Saidha S, Sotirchos ES, Ibrahim MA, Crainiceanu CM, Gelfand JM, Sepah YJ, Ratchford JN, Oh J, Seigo MA, Newsome SD, Balcer LJ, Frohman EM, Green AJ, Nguyen QD, and Calabresi PA. Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet neurology 11: 963-972, 2012.

175. Saidha S, Sotirchos ES, Oh J, Syc SB, Seigo MA, Shiee N, Eckstein C, Durbin MK, Oakley JD, Meyer SA, Frohman TC, Newsome S, Ratchford JN, Balcer LJ, Pham DL, Crainiceanu CM, Frohman EM, Reich DS, and Calabresi PA. Relationships Between Retinal Axonal and Neuronal Measures and Global Central Nervous System Pathology in Multiple Sclerosis. Archives of neurology 1-10, 2012.


39

176. Seigo MA, Sotirchos ES, Newsome S, Babiarz A, Eckstein C, Ford E, Oakley JD, Syc SB, Frohman TC, Ratchford JN, Balcer LJ, Frohman EM, Calabresi PA, and Saidha S. In vivo assessment of retinal neuronal layers in multiple sclerosis with manual and automated optical coherence tomography segmentation techniques. Journal of neurology 259: 2119-2130, 2012.

177. Syc SB, Saidha S, Newsome SD, Ratchford JN, Levy M, Ford E, Crainiceanu CM, Durbin MK, Oakley JD, Meyer SA, Frohman EM, and Calabresi PA. Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain : a journal of neurology 135: 521-533, 2012.

178. Walter SD, Ishikawa H, Galetta KM, Sakai RE, Feller DJ, Henderson SB, Wilson JA, Maguire MG, Galetta SL, Frohman E, Calabresi PA, Schuman JS, and Balcer LJ. Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology 119: 1250-1257, 2012.

179. Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, St√ºve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Ikl√© D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C, Zamvil SS; ITN STAyCIS Study Group; ITN020AI Study Management Team. Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Neurology. 2012 Apr10;78(15):1171-8.

180. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012 Nov 24;380(9856):1829-39

181. Beh SC, Greenberg BM, Frohman T, and Frohman EM. Transverse myelitis. Neurologic clinics 31: 79-138, 2013.

182. Minagar A, Barnett MH, Benedict RH, Pelletier D, Pirko I, Sahraian MA, Frohman E, and Zivadinov R. The thalamus and multiple sclerosis: Modern views on pathologic, imaging, and clinical aspects. Neurology 80: 210-219, 2013.

183. Ratchford JN, Saidha S, Sotirchos ES, Oh JA, Seigo MA, Eckstein C, Durbin MK, Oakley JD, Meyer SA, Conger A, Frohman TC, Newsome SD, Balcer LJ, Frohman EM, and Calabresi PA. Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning. Neurology 80: 47-54, 2013.

184. Saidha S, Sotirchos ES, Oh J, Syc SB, Seigo MA, Shiee N, Eckstein C, Durbin MK, Oakley JD, Meyer SA, Frohman TC, Newsome S, Ratchford JN, Balcer LJ, Pham DL, Crainiceanu CM, Frohman EM, Reich DS, and Calabresi PA. Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosis. JAMA neurology 70: 34-43, 2013.


40

185. Fletcher SG, Dillon BE, Gilchrist AS, Haverkorn RM, Yan J, Frohman EM, Lemack GE. Renal deterioration in multiple sclerosis patients with neurovesical dysfunction. Mult Scler 2013;19:1169-1174.

186. Horton L, Conger A, Conger D, Remington G, Frohman T, Frohman E, Greenberg B. The effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy. Neurology, 2013;80:1862-1866.

187. Minagar A, Barnett MH, Benedict RH, Pelletier D, Pirko I, Sahraian MA, Frohman E, Zivadinov R. The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects. Neurology. 2013;80:210-9.

188. Frohman TC, Beh S, Saidha S, Schnurman Z, Conger D, Conger A, Ratchford JN, Lopez C, Galetta S, Calabresi PA, Balcer LJ, Green AJ, Frohman EM. The optic nerve head component response of the multifocal electroretinogram in MS. Neurology 2013;81:545-551.

189. Sotirchos ES, Saidha S, Byraiah G, Mealy MA, Ibrahim MA, Sepah YJ, Newsome SD, Ratchford JN, Frohman EM, Balcer LJ, Crainiceanu CM, Nguyen QD, Levy M, Calabresi PA. In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology. 2013;80:1406-1414.

190. Frohman TC, Davis SL, Beh S, Greenberg BM, Remington G, Frohman EM. Uhthoff’s Phenomena in Multiple Sclerosis:Clinical Characterization and Pathophysiologic Mechanisms. Nature Neurology 2013;9:535-540.

191. Major G, Frohman EM, Douek D. JC viremia in natalizumab-treated patients

with multiple sclerosis patients. N Engl J Med 2013;368:2240-2241. 192. Major EO, Douek DC, Frohman EM, Walsh DR. Two demyelinating diseases in

the brain of a single patient, PML and MS: how to minimize 'one' while treating the 'other'. Expert Rev Clin Immunol. 2013;9:887-890.

193. Major EO, Frohman E, Douek D. More on JC viremia in natalizumab-treated

patients with multiple sclerosis. N Engl J Med. 2013;369:1280. 194. Beh SC, Frohman TC, Frohman EM. Isolated mammillary body involvement on

MRI in Wernicke's encephalopathy. J Neurol Sci. 2013;334:172-175. 195. Muppidi S, Adams-Huet B, Tajzoy E, Scribner M, Blazek P, Spaeth EB,

Frohman E, Davis S, Vernino S. Dynamic pupillometry as an autonomic testing tool. Clin Auton Res. 2013;23:297-303.

196. Greenberg BM, Balcer L, Calabresi PA, Cree B, Cross A, Frohman T, Gold R,

Havrdova E, Hemmer B, Kieseier BC, Lisak R, Miller A, Racke MK, Steinman L, Stuve O, Wiendl H, Frohman E. Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol. 2013;70:248-251.


41

197. Greenberg BM, Frohman E. Interferon beta and long-term disability in multiple

sclerosis--reply. JAMA Neurol. 2013;70:652-653. 198. Ligocki AJ, Rounds WH, Cameron EM, Harp CT, Frohman EM, Courtney AM,

Vernino S, Cowell LG, Greenberg B, Monson NL. Expansion of CD27high plasmablasts in transverse myelitis patients that utilize VH4 and JH6 genes and undergo extensive somatic hypermutation. Genes Immun. 2013;14:291-301.

199. Ayers CL, Mendoza JP, Sinha S, Cunnusamy K, Greenberg BM, Frohman EM,

Karandikar NJ. Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis. Clin Immunol. 2013;147:105-119.

200. Waldman AT, Hiremath G, Avery RA, Conger A, Pineles SL, Loguidice MJ, Talman LS, Galetta KM, Shumski MJ, Wilson J, Ford E, Lavery AM, Conger D, Greenberg BM, Ellenberg JH, Frohman EM, Balcer LJ, Calabresi PA. Monocular and binocular low-contrast visual acuity and optical coherence tomography in pediatric multiple sclerosis. Mult Scler Relat Disord. 2013 May 1;3(3):326-334.

201. Rommer PS, Zettl UK, Kieseier B, Hartung HP, Menge T, Frohman E, Greenberg BM, Hemmer B, Stüve O. Requirement for safety monitoring for approved MS therapies - An overview. Clin Exp Immunol. 2014;175:397-407.

202. Frohman, EM, Monacqo, MC, Remington, G, Ryschkewitsch, C, Jensen, PN,

Johnson, K, Perkins, M, Liebner, J, Greenberg, B, Monson, N, Frohman, TC, Douek, D, Major, EO. JC Virus in CD34+ and CD19+ cells in MS patients treated with natalizumab. JAMA Neurol 2014;71:596-602.

203. Schnurman Z, Frohman TC, Beh SC, Conger D, Conger A, Saidha S, Galetta S,

Calabresi PA, Green AJ, Balcer LJ, Frohman EM. Retinal architecture and mfERG Optic nerve head component response characteristics in MS. Neurology 2014;82:1888-1896.

204. Cunnusamy K, Baughman EJ, Franco J, Ortega SB, Sinha S, Chaudhary P,

Greenberg BM, Frohman EM, Karandikar N. Disease exacerbation of multiple sclerosis is characterized by loss of terminally differentiated autoregulatory CD8+ T cells. Clin Immunol 2014;152:115-126.

205. Sakaie K, Takahashi M, Sagiyama K, Dimitrov I, Frohman T, Remington G,

Frohman E, Fox RJ. Injury to a specific neural pathway detected by Ultra-high-field MRI. Neurology. 2014; 82:182-183.


42

206. Schippling S, Balk L, Costello F, Albrecht P, Balcer L, Calabresi P,

Frederiksen J, Frohman E, Green A, Klistorner A, Outteryck O, Paul F, Plant G, Traber G, Vermersch P, Villoslada P, Wolf S, Petzold A. Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria. Mult Scler. 2014;ahead of print.

207. Qureshi SS, Beh SC, Frohman TC, Frohman EM. An update on neuro-

ophthalmology of multiple sclerosis: the visual system as a model to study multiple sclerosis. Curr Opin Neurol. 2014;27:300-308.

208. Beh SC, Conger D, Conger A, Frohman TC, Sutter EE, Schnurman Z, Calabresi

PA, Green A, Balcer LJ, Frishman L, Frohman EM. The optic nerve head component of the normal human multifocal electroretinogram. JNNP (in prep)

209. Keller, DM, Fadel, PJ, Remington, GM, Frohman, EM, Davis, SL. Reduced

Spontaneous Sympathetic Nerve Activity in Multiple Sclerosis Patients. J Neurol Sci (in press).

210. Beh, et al. MS Part I. What is MS? 211. Beh, et al. MS Part II. Treating the disease. 212. Sakaie K, Takahashi M, Remington G, Wang X, Conger A, Conger D, Dimitrov I,

Frohman A, Frohman T, Sagiyama K, Togao O, Fox RJ, Frohman EM. Correlating Function and Imaging Measures of the Medial Longitudinal Fasciculus. (in preparation)

BOOK CHAPTERS: 1. Frohman, E.M., and Zee, D. Supranuclear eye movement abnormalities. In Easty, D.L., Sparrow, J.M., eds. Oxford Textbook of Ophthalmology 1999 2. Frohman, E.M. Treatment for patients with relapsing remitting MS. In Multiple Sclerosis Therapeutics, Rudick, R., and Goodkin, D. eds. Dunitz, London 1999, Pp 415-442. 3. Frohman, E.M. Vision. In Multiple Sclerosis in Clinical Practice. Van den Noort, S., and Holland, Nancy (eds.) Demos, New York 1999, pp. 89-97. 4. Frohman, E.M., Zimmerman, C., Frohman, T.C. Neuro-Ophthalmic Signs and Symptoms in MS. In Multiple sclerosis:Diagnosis, medical management, and


43

rehabilitation. Signs in Multiple Sclerosis. Burks, J., Johnson, K., eds. Demos, New York 2000, pp. 341-375. 5. Frohman, E.M. Bladder and sexual dysfunction in MS and spinal cord diseases. In Current Therapy in Neurological Diseases. Johnson, R.T., Griffin, J., McArthur, J. eds. Mosby, St Louis, 2001, pp. 188-192. 6. Hawker, K., Frohman, E.M. Incontinence and sexual dysfunction in the elderly. In Clinical Neurology in Older Adults. Sirven, J., Malamut, B. eds. Lippincott. 7. Frohman, E.M. Evaluation of the dizzy patient. In Scientific American Medicine. Dale, D.C., Federman, D.D. eds. WebMD, New York. 2003, pp. 2023-2035. 8. Frohman, E.M. Optic Neuritis. In The 5 minute Neurology Consult, Lynn, D.J., Newton, H.B., Rae-Grant, A.D., eds. Lippincott Williams & Wilkins, Philadelphia, 2004, pp. 324-325. 9. Solomon, D., Frohman, E.M: 1 The Dizzy Patient. 11 Neurology. ACP Medicine Online. Dale, D.C., Federman, D.D., Eds. WebMD Inc., New York, 2005. http://acpmedicine.com, March, 2005. 10. Use of imaging in multiple sclerosis. M. Filippi, M.A. Rocca, D.L. Arnold, R. Bakshi, F. Barkhof, N. De Stefano, F. Fazekas, E. Frohman, J.S. Wolinsky. In European Handbook of Neurological Management. Hughes, R., Brainin, M., Gilhus, N.E., eds. Blackwell Publishing, Williston, Vermont. 2006. 11. Woo, D., Frohman, T.C., Frohman, E.M. Vestibular testing in multiple sclerosis. In Vertigo and Imbalance: Clinical Neurophysiology of the Vestibular System. Zee, D.S., Egger, S. eds. Elsevier, Amsterdam, 2010, pp. 478-486. 12. Ko, E., Vaish, S., Frohman, E.M., Wingerchuk, D. Incontinence and sexual dysfunction in the elderly. In Clinical Neurology of Older Adults. Sirven, J., Malamut, B., eds. Lippincott (in press) 13. Shah, A., Bates, A., Davis, S., Lemack, G., Frohman, T., Frohman, E.M. Symptomatic therapy for MS. In Blue Book of Neurology. Lucchinetti, C, Hohlfeld, R. eds. Saunders Elsevier, Philadelphia, 2010, pp. 316-354. 14. Frohman, E.M. The Dizzy Patient. American College of Physicians Medicine (ACP Medicine) (in press). 15. Burton, E., Frohman, E.M. Neuro-Ophthalmology of MS. In Primer of Multiple Sclerosis. Giesser, B, ed. Oxford University Press (in press)


44

16. M. Filippi, M.A. Rocca,a D.L. Arnold, R. Bakshi, F. Barkhof, N. De Stefano, F. Fazekas, E. Frohman, J.S. Wolinsky. Use of imaging in multiple sclerosis. Handbook of Neurological Disorders (in press). 17. Cravens, P., Eager, T., Karandikar, N., Monson, N., Stuve, O., Frohman, E.M. Neuroimmunology of multiple sclerosis. In Multiple Sclerosis for the Physician Assistant, Frohman, TC ed. Demos Press, New York, 2011; pp 13-20. 18. Courtney, A., Frohman, E.M. Neuroimaging and multiple sclerosis. In Multiple Sclerosis for the Physician Assistant, Frohman, TC ed. Demos Press, New York, 2011; 21-43. 19. Frohman, E.M. Disease modifying interventions. In Multiple Sclerosis for the Physician Assistant, Frohman, TC ed. Demos Press, New York, 2011;58-70. 20. Frohman, E.M. Treatment of acute exacerbations. In Multiple Sclerosis for the Physician Assistant, Frohman, TC ed. Demos Press, New York, 2011;71-81. 21. Logan, D., Frohman, T.C., Frohman, E.M., Hart, J. Depression and cognitive changes. In Multiple Sclerosis for the Physician Assistant, Frohman, TC ed. Demos Press, New York, 2011;91-97. 22. Davis, S.L., Frohman, E.M. Heat sensitivity:Uhthoff’s phenomenon. In Multiple Sclerosis for the Physician Assistant, Frohman, TC ed. Demos Press, New York, 2011;98-101. 23. Frohman, T.C., Frohman, E.M. Vestibular dysfunction. In Multiple Sclerosis for the Physician Assistant, Frohman, TC ed. Demos Press, New York, 2011;138-141. BOOK EDITOR Optical Coherence Tomography in Neurological Disease Calabresi, PA, Balcer, LJ, Frohman, EM eds. Cambridge University Press (in preparation). First book on the subject of OCT in neurological disease


45

MONOGRAPHS: 1. Frohman, E.M. Neuro-Urology of multiple sclerosis, myelopathies, and spinal cord injury. World Federation of Neurology Website 2. Fowler, C., Frohman, E.M. Neurogenic sexual dysfunction in men and women. World Federation of Neurology Website 3. Hawker, K., Frohman, E.M. Bowel, bladder, and sexual dysfunction in MS. Current Treatment Options in Neurology 2001;3:207-214. 4. Frohman, E.M. Diagnosis and management of vision problems in MS. National MS Society Clinical Bulletin 2001. 5. Disease modifying therapies in MS:Evidence-based management strategies. MS Council for Clinical Practice Guidelines. Supported by Paralyzed Veterans of America. Frohman, E.M. and van den Noort, S., Co-Chairs. 6. Frohman, E.M. Dr. Elliot Frohman on managing injection site reactions. Inside MS (magazine of the National MS Society). April-May issue 2005;62-63. 7. Frohman, T.C., Graves, J., Galetta, S., Balcer, L.J., Frohman, E.M. The neuro-ophthalmology of MS. American Academy of Neurology, Continuum 2010 8. Sadowsky, C, Becker, D, Bosques, G, Dean, J, McDonald, JW, Recio, A, Frohman, EM. Rehabilitation in Transverse Myelitis. American Academy of Neurology, Continuum (in press). EDITORIALS & LETTERS: 1. Frohman, E.M., van den Noort, S., Racke, M. To treat, or not to treat:The therapeutic dilemma of Idiopathic monosymptomatic demyelinating syndromes. Archives of Neurology 2000;57:930-932.

2. Racke, M.K., Hawker, K., Frohman, E.M. Multiple sclerosis and magnetic resonance imaging: Advancement in linking the pictures with the progression. Archives of Neurology 2001;58:35-36. 3. Racke, M.K., Hawker, K., Frohman, E.M. Fatigue in MS: Is the picture getting simpler or more complex? Archives of Neurology 2004;61:176-177. 4. Frohman, E.M. What effect does pregnancy have on MS relapse rate. Journal Watch Neurology (published by New England Journal of Medicine). 2004;6:73-74.


46

5. Goodin, D.S., Frohman, E.M. Overdiagnosis of multiple sclerosis by magnetic resonance imaging. Ann Neurol 2006;59:575-576. 6. Frohman, E., Zivadinov, R. What you see is what you get:Coupling function with structure in the visual system. Neurology 2007;69:2119-2120. 7. Weinshenker, B, Galetta, S, Bennett, J, Kerr, D, Frohman, EM. Lumpers and Splitters Respond. Arch Neurol (in press) 8. Nash RA, Stuve O, Bowen JD, Frohman EM, Griffith LM, Hutton GJ, Kraft GH, Popat U, Racke MK, Muraro PA. Autologous HSCT for advanced MS: Is the glass half-empty or really half-full? Brain. 2007 Sep 30; 9. Phillips, JT, Frohman, EM. Natalizumab:Benefit outweights risk in selected patients with multiple sclerosis. Ther Adv Neurol Dis 2008;1:151-153. OBITUARIES 1. Frohman, E.M., Stuve, O., Miller, D. W. Ian McDonald Obituary:The MS Physician-Scientist of the 20th Century. Arch Neurol 2007;64:452-454. 2. Frohman, E.M. In Memorium:Stanley van den Noort. Neurology 2010;

BOOK REVIEWS: 1. Frohman, E.M. Interferon therapy of multiple sclerosis. Reder, A., ed. New York:Marcel Dekker, 1997. Ann Neurol 1998;44:297-298. 2. Frohman, E.M. Neurology of bladder, bowel, and sexual dysfunction. Fowler, C.J., ed. Boston:Butterworth Heinemann, 1999. Ann Neurol 3. Frohman, E.M. New frontiers of MR-based techniques in multiple sclerosis. Filippi, M., Comi, G., eds. Milan:Spriner, 2003. Arch Neurol ABSTRACTS:Not Listed and Not Available

TEACHING PORTFOLIO COURSE SYLLABI: 1. Frohman, E.M. Multiple sclerosis and Vertigo. Neurology Clerkship Syllabus. UT


47

Southwestern Medical School. 2. Frohman, E.M. The vestibular system. 1st year medical student neurosciences course. UT Southwestern Medical School. 3. Frohman, E.M. Sexual dysfunction in neurological disease. In:Introduction to Neuro-Urology. Half day course. American Academy of Neurology Annual Meeting 2000 4. Frohman, E.M. Adjuctive Therapy for MS. In:ABCs…DEFs of Immunotherapy for MS Half day course. American Academy of Neurology Annual Meeting 2000 5. Frohman, E.M. Urinary incontinence. Progress in Clinical Therapeutics. UT Southwestern CME May 10-12, 2002. TEACHING: 1982 Teacher Assistantship Anthropology of Medicine Department of Anthropology University of California, San Diego 1986, 1988 Teaching Assistant and Laboratory Demonstrator Medical School Neuroanatomy California College of Medicine University of California, Irvine 1986 Tutor for the Neuroanatomy & Physiology courses California College of Medicine University of California, Irvine SPECIFIC EDUCATIONAL ACTIVITIES: National Courses/International Courses 2000, 2001, 2002, 2003 Introduction to Neuro-Urology (Chairman) American Academy of Neurology Annual Meeting 2000, 2001 ABCs of Immune Modulating Therapy in MS American Academy of Neurology Annual Meeting 2004 Neurology Crossfire-MS American Academy of Neurology Annual Meeting San Francisco


48

2004 Use of Evidence Based Assessments American Academy of Neurology Annual Meeting San Francisco 2005, 2006 Update on MS (full day course) Comprehensive Symptom Management American Academy of Neurology Annual Meeting Miami 2005 Multiple Sclerosis Therapy (Therapy Program) Treating Breakthrough and Progression American Academy of Neurology Annual Meeting Miami 2006 Update on MS (full day course) Comprehensive Symptom Management American Academy of Neurology Annual Meeting San Diego 2006 The Changing View of Multiple Sclerosis Neuromyelitis Optica:Is it distinct from MS? Program Chairman-CME National Symposium UT Southwestern/U Penn/Mayo Clinic 2007 Multiple Sclerosis Update (Aaron Miller, Chair) When Interferons and Glatiramer Acetate are not Enough American Academy of Neurology Annual Meeting Boston 2007 Bowel, Bladder, and Sexual Dysfunction in MS

Mayo Clinic National Neurology Review on MS Scottsdale, Arizona 2007 European Committee for Treatment &Research in MS Ongoing Disease Activity Despite DMT Program Co-Chair Prague, Czech Republic 2007 International Workshop Management of Central and Peripheral Vertigo Multiple Sclerosis Istituto Scientifico Universitario San Raffaele, Milano, Italy


49

2007 A Think Tank on the Challenges of Treating MS Co-Chairman with Benjamin Greenberg Johns Hopkins CME National Teaching Course 2008 Treating Multiple Sclerosis American Academy of Neurology Winter Meeting Miami, Florida 2008 Multiple Sclerosis Update American Academy of Neurology Winter Meeting New Orleans, Louisiana 2009 Symptom Management of MS Update on MS Course American Academy of Neurology Annual Meeting Seattle, Washington 2009 Multiple Sclerosis Neurologic Therapeutics Course American Academy of Neurology Annual Meeting Seattle, Washington 2009 Symptom Management of MS European Committee for Treatment and Research MS Dusseldorf, Germany 2009 Sexual Dysfunction in MS European Committee for Treatment and Research MS Dusseldorf, Germany 2010 NeuroFlash MS-Course Chairman American Academy of Neurology Annual Meeting Toronto, Canada 2010 Rare Neuroimmunological Disorders Symposium Co-Chairman with Benjamin Greenberg Dallas, Texas 2010 Optic Neuritis as a Model for Stem Cell Therapy in MS Heat Intolerance in MS Rare Neuroimmunological Disorders Symposium Dallas, Texas 2010 Symptom Management in MS European Committee for Treatment and Research MS


50

Gothenberg, Sweden 2011 Vision in MS (co-Chairman) American Academy of Neurology Honolulu, Hawaii 2011 Pupillary reflex metrics in MS:Objective Characterization of the afferent pupillary defect. Platform Presentation (Vision in MS section) American Academy of Neurology Honolulu, Hawaii 2011/2012 Addressing the challenges of risk assessment and risk management in MS-Co Director MS-Leaders on-line program and monograph A Johns Hopkins CME Activity 2012 Managing Symptoms in MS CME Teaching Course on MS American Academy of Neurology New Orleans, Louisiana 2012 Modeling Neuroprotection in the Visual System Keynote Lecture Brazilian Committee for Research and Treatment of MS Igazu Falls, Brazil 2012 Melanocortins and Neuroprotection in the CNS Chairman Lyon, France 2013 Multiple Sclerosis Update on Treatment Texas Neurological Society Austin, Texas 2013 Real Neurologists do Heads and Tails Managing Symptoms in MS American Academy of Neurology San Diego, California 2013 The Ins and Outs of Bowel, Bladder and Sexual

Dysfunction in MS American Academy of Neurology


51

San Diego, California Ongoing, Recurrent UT Southwestern Teaching Activites: 1995-present Senior medical student neurology course 1995-present Instructor-First and second year medical student

neuroscience course 1995-present Multiple Sclerosis and Vertigo-Monthly Lecture for 4th year

Medical Students-Performed Independently until the recent recruitment of additional MS Faculty.

1995-present Clinical Exam Skills Course-Medical Students and

Neurology Residents 1995-present Ambulatory Neurology Rotation for Residents and Medical

students (Daily to weekly) 1995-present Neuro-Ophthalmology Lecture series Neurology Resident lecture series (three lectures/yr) 1995-present Evaluation of the dizzy patient Neurology Resident lecture series (one lecture/yr) 2003- STARS Program-MS and the Brain Lectures and brain cutting for 16 7th graders Winston School, Dallas LECTURES & TEACHING ACTIVITIES AT UT SOUTHWESTERN: 1995 Neuroimmunology Medical Student Neurology Clerkship (monthly lecture) University of Texas Southwestern Medical Center 1995 Evaluation of the Dizzy Patient (Yearly) Neurology Resident Lecture Series University of Texas Southwestern Medical Center 1995-present Horizontal Eye Movements Neuro-ophthalmology lecture series (yearly) Department of Ophthalmology University of Texas Southwestern Medical Center


52

1995-present Vertical Eye Movements Neuro-ophthalmology lecture series (yearly) Department of Ophthalmology University of Texas Southwestern Medical Center 1995-present Vestibular Control of Eye Movements Neuro-ophthalmology lecture series (yearly) Department of Ophthalmology University of Texas Southwestern Medical Center 1995 Evaluation of the Dizzy Patient Update in Neurology for primary care physicians Zale Lipshy University Hospital, UT Southwestern 1995 Gallup Rounds-Multiple Sclerosis and Neuro-otology UT Southwestern Medical Center 1996-present A Dynamic Survey of Nystagmus Neuro-ophthalmology lecture series (yearly) Department of Ophthalmology University of Texas Southwestern Medical Center 1996- Congenital Nystagmus Neuro-opthalmology lecture series (yearly) Department of Ophthalmology University of Texas Southwestern Medical Center 1996 Non-vestibular causes of dizzyness Oto-rhino-laryngology Grand Rounds University of Texas Southwestern Medical Center 1996 Science of Family Practice Symposium (CME) Evaluation of the Dizzy Patient UT Southwestern 1997 Multiple Sclerosis:A Multidisciplinary Framework Physical Medicine and Rehabilitation Grand Rounds UT Southwestern Medical Center 1997 Current Concepts in Multiple Sclerosis Physical Medicine & Rehab Grand Rounds UT Southwestern Medical Center at Dallas 1997 MS:From Viking Sagas to Emerging Treatment Neurology Grand Rounds


53

UT Southwestern Medical Center 1998 Acute & Chronic Inflammatory Demyelinating

Polyneuropathy Physical Medicine & Rehabilitation Grand Rounds

UT Southwestern Medical Center 1998 Evaluation of the dizzy patient Internal Medicine Grand Rounds UT Southwestern Medical Center 2000 Multiple Sclerosis Allied Health Grand Rounds UT Southwestern Medical Center 2000 Evaluation of the Dizzy Patient Otolaryngology Grand Rounds UT Southwestern 2001 Analysis of Visual Deficits in Patients with Optic Gliomas

Department of Ophthalmology-Resident Education Day Commentator-Ophthalmology Resident Presentation 2000 Multiple Sclerosis Dallas Internist Club 2000 Multiple Sclerosis Update PM&R Grand Rounds UT Southwestern 2001 MS & The Non-neurologist Course Chairman and Lecturer 2002 President’s Research Council Lecture MS:Translating basic science from the bench to the bedside UT Southwestern 2002 Progress in Clinical Therapeutics Course Urinary Incontinence UT Southwestern CME course. 2002 Multiple Sclerosis Annual Internal Medicine Update UT Southwestern CME course


54

2002 Multiple Sclerosis Visiting Professor Rounds St. Paul Hospital, Dallas 2004 Multiple Sclerosis:Treating the Disease Neurology Grand Rounds UT Southwestern Medical Center 2004 Eloquent Neuro-Ophthalmologic Models of Tissue Injury Zimmerman Memorial Lecture Department of Ophthalmology UT Southwestern Medical Center 2004 Multiple Sclerosis Internal Medicine Grand Rounds UT Southwestern 2006 Modeling Neuroprotection in the RNFL of Optic Neuritis Frontiers in Clinical Trial Design Course UT Southwestern 2006 Neuromyelitis Optica:Is it distinct from MS? Program Chairman-CME Symposium UT Southwestern 2007 Modeling Pathophysiology and Neuroprotection in MS Neurology Grand Rounds UT Southwestern 2007 Neuro-Ophthalmology (Eye Movements and Nystagmus) Resident Teaching Dinner Symposium 2007 Neuro-Ophthalmology (Assessment of Double Vision) Resident Teaching Dinner Symposium 2007 Modeling Neuroprotection in the Anterior Visual System Carol Zimmerman Memorial Lecture Series UT Southwestern Medical Center 2008 Physical Medicine & Rehabilitation Annual Research Symposium Modeling Pathophysiology and Neuroprotection in MS 2009 ‘Fun with the Fundus’:Neuro-Ophthalmology Series


55

Annual Neurology Resident Education UT Southwestern Medical Center 2013 ‘Eye-ing a Window of Neuroprotection in the Visual System for Multiple Sclerosis Capra Research Symposium Keynote Lecture School of Health Professions UT Southwestern Medical Center Annual Neurology Resident Teaching MS, Neuroimmunology, Neurorehab One month block (Director) 2013-2014 ‘Fun with Frohman’ Lectures Monthly Dinner Lecture (6pm-10 to Midnight) Various Topics (Fundus, Diplopic Patient, Vestibular) INVITED LECTURES (Outside UT Southwestern): 1987 Research Symposium on Aging University of California, Irvine Norepinephrine antagonizes g-IFN induction of class II MHC antigens on cultured brain astrocytes 1988 Grand Rounds Lecture Department of Neurology Stanford University School of Medicine Regulation of brain immune responses (delivered this Grand Rounds as an MSTP student) 1989 Grand Rounds Lecture Department of Neurology University of California, Irvine Neuroimmunology in neurological disease 1989 Grand Rounds Lecture Department of Neurology University of California, Irvine Neuroanatomy of the limbic system 1989 Orange County Multiple Sclerosis Society Current Developments in MS Research Irvine, CA


56

1990 National Multiple Sclerosis Society and NINCDS The role of astrocytes in inflammatory demyelination: MHC expression and antigen presentation Galveston, Texas 1993 Mechanisms of Inflammatory Demyelination Neurology Grand Rounds University of California, Irvine 1993 Regulation of brain immune responses Neurology and Neurosurgery Grand Rounds University of Tennessee, Memphis 1993 Harvard Medical School Gordon Conference Biology of the Immune Response to Antigen Within the CNS Colby-Sawyer College, New Hampshire 1994 Mechanisms of CNS Immunoprivilege Department of Neurology University of California, San Francisco 1994 Carotid cavernous fistulas Neurology Grand Rounds Johns Hopkins Hospital 1994 Ocular Neuromyotonia Neurology Grand Rounds Johns Hopkins Hospital 1994 Mechanisms of CNS Immunoprivilege Neurology Grand Rounds Emory University, Atlanta Georgia 1994 The Brain:From Seat Of The Soul To Master Computer: An Odyssey Through The History Of Medicine Royal Cruise Line to Italy, Greece, and France 1994 Mechanisms in Eye Movement Abnormalities Neurology Grand Rounds University of Louisville School of Medicine 1995 The Brain:From Seat Of The Soul To Master Computer: An Odyssey Through The History Of Medicine


57

Royal Cruise Line to the Panama Canal 1995 The Balancing Act in Multiple Sclerosis The Multiple Sclerosis Society Dallas, Texas 1995 The Balancing Act in Multiple Sclerosis The MS Society Fort Worth, Texas 1996 Multiple Sclerosis Texas Rehabilitation Commision Dallas, Texas 1996 Multiple Sclerosis Society Plano Richardson Support Group Plano, Texas 1996 National Multiple Sclerosis Annual Meeting North Texas Chapter MS Overview for the Newly Diagnosed Patient 1996 Multiple Sclerosis Update Internal Medicine Grand Rounds Presbyterian Hospital, Dallas, TX 1996 The Ins and Outs of Bowel, Bladder, and Sexual Dysfunction in MS National MS Society, Fort Worth Chapter 1996 The Balancing Act in MS Keynote Address for the Annual Meeting National MS Society, San Antonio, TX 1996 The Ins and Outs of Bowel, Bladder, and Sexual Dysfunction in MS National MS Society, San Antonio, TX 1996 Advances in Multiple Sclerosis Research University of California, Irvine MD/PhD Retreat Keynote Lecturer Lake Arrowhead, California 1997 Internal Medicine Grand Rounds Advances in Multiple Sclerosis Research


58

University of Nebraska School of Medicine 1997 The balancing act in multiple sclerosis Current Concepts in Multiple Sclerosis MS Society Professional Education Symposium Dallas, Texas 1997 Symptomatic therapy & Rehabilitation of MS Current Concepts in Multiple Sclerosis MS Society Professional Education Symposium Dallas, Texas 1997 Current Concepts in Multiple Sclerosis Neurology Grand Rounds Texas Tech University El Paso, Texas 1997 Neurological Exam of the MS Patient Nurse Consultants Meeting on MS Dallas, Texas 1997 New Treatments for Multiple Sclerosis Denton MS Society support group 1997 Multiple Sclerosis--Treatments Emerge Columbia Hospital at Medical City Dallas, Texas 1997 Multiple Sclerosis--Treatments Emerge MS Society Dinner Lecture Wichita, Kansas 1997 MS Society Annual Education Conference Progressive forms of MS Plano, Texas 1997 MS Society Teleconference Evaluating new treatments for MS 1997 The Neurological Exam Clinical Nurse Symposium Davenport, Iowa 1997 Advancements in Multiple Sclerosis National MS Society Education Conference


59

Illinois and Iowa Chapters 1997 New Advances in MS Research Community Lecture for Physicians Davenport, Iowa 1997 New Advancements in MS Community Lecture for Neurologists Denver, Colorado 1997 Neuro-Ophthalmology of MS Neurology Grand Rounds UT Houston 1997 Kansas City Southwest Clinical Society

Update on Multiple Sclerosis Kansas City, MO

1997 Midlands Chapter of the National MS Society

MS Update 1997 Omaha, Nebraska 1997 New Advancements in MS

Community Lecture for Neurologists Omaha, Nebraska

1997 Interferon beta 1a in MS

Fachklinik Fur Neurologie-Neurology Grand Rounds Dietenbronn, Germany

1997 National MS Society Leadership Conference Research Update-Panelist with Drs. Stephen Hauser and Stephen Reingold

1998 Austrian Neurological Society Update on Interferon Therapy in MS Vienna, Austria 1998 Symptomatic Therapies in MS

Neurology Grand Rounds University of Nebraska Omaha, Nebraska

1998 Neuro-Ophthalmic Manifestations of MS

Neurology Grand Rounds


60

Wayne State University Detroit, MI

1998 Treating MS:Slowing the progression National MS Society Education Conference Colorado Springs, CO

1998 Neuro-ophthalmology of MS

Neurology Grand Rounds University of California, Irvine

1998 Advances in MS Therapy

Orange County Neurological Society Irvine, California

1998 Update on MS Teleconference

National MS Society Orange County Chapter

1998 Multiple Sclerosis National MS Society Support Group Northridge, California 1998 A Patient Centered Therapeutic Framework for MS: An

International Conference on Models of Care Dallas, Texas

1998 A Patient Centered Therapeutic Approach to MS

Neuro-Ophthalmology of MS A Continuing Education Conference

1998 MS:Treating the Disease and its Symptoms

New Horizons Health & Wellness Conference Hot Springs, Arkansas 1998- MS Society Annual Education Conference

New Developments in MS Research & Treatment Sioux Falls, South Dakota 1998 Evaluation of the dizzy patient

Internal Medicine Grand Rounds Dallas VA Hospital

1998 National MS Society Iowa Chapter Annual Education Meeting Keynote Speaker


61

1998 Australian Launch of interferon b1a Immunopathogenesis & Early Treatment Sydney, Brisbane, Melbourne, Adelaide, Perth 1999 Texas Neurological Society (CME) Evaluation of the Dizzy Patient Austin, Texas 1999 MS:Immunopathogenesis & Treatment Internal Medicine Visiting Professor St. Paul Medical Center Dallas, TX 1999 New Advancements in MS Research

Plano-Richardson MS Support Group Plano, Texas

1999 Clinical Research Update on MS

National MS Society Keynote Speaker Lubbock, Texas

1999 MS Therapy:Optimizing Patient Care Banff, Alberta Canada

1999 Multiple Sclerosis Update for Neurologists Philadelphia, PA

1999 Symptomatic Management in MS (CME) Canadian Congress of Neurological Sciences

Edmonton, Canada 1999 Models of Care for MS-Course Director (CME) Consortium of MS Clinics Kansas City, MO 1999 Comprehensive Management for MS 24th Congreso Agentino de Neurociencias Mar del Plata, Argentina 1999 Comprehensive Management of MS Neurology Grand Rounds University of Iowa, Iowa City 1999 MS and the Mind Monterey, California


62

1999 Mulitple Sclerosis Update Family Practice Dept. Methodist Hospital, Dallas 1999 MS Update National MS Society Orange County, CA 1999 MS Update National MS Society San Diego, CA 1999 Bowel, Bladder, Sexual Dysfunction in MS National MS Society St. Louis, MO 1999 Women’s Issues in MS Neurology Grand Rounds Lecture St. Louis University 1999 IFNb1a in Advanced Forms of Relapsing MS ACTRIM/ECTRIMS Meeting, Basel, Switzerland Satellite Symposium 1999 Internuclear Ophthalmoplegia in MS Neurology Grand Rounds Lecture University of Zurich, Switzerland 1999 Multiple Sclerosis:The Rationale for Early Treatment Neurological Congress of Uruguay-Keynote Lecture Montevideo, Uruguay 1999 The Rationale for Early Treatment of MS Neurology Grand Rounds University of South Dakota 1999 The Rationale for Early Treatment of MS National MS Society Annual Keynote Lecture Sioux Falls, South Dakota 1999 MS in the New Millenium Update for Community Physicians Sioux Falls, South Dakota


63

1999 MS in the New Millenium Mexican Neurological Congress Keynote Lecture Cabo San Lucas, Mexico 1999 Neuro-Ophthalmology of MS Neurology Grand Rounds Mayo Clinic 1999 Evaluation of the Dizzy Patient Resident Lecture Mayo Clinic 1999 Keynote Address National MS Society Annual Meeting Detroit, MI 1999 Building Hope (MS Community Lecture) Houston, Texas 1999 Frontline Neurology Symposium(CME) 1. MS:From Viking Sagas to Emerging Therapies 2. Comprehensive Management of MS Minneapolis, MN 2000 Introduction to Neuro-Urology (half-day course) (CME) Course Chairman and Lecturer Sexual Dysfunction in neurological disease American Academy of Neurology, San Diego 2000 Adjunctive Therapy for MS Patients (half-day course) ABCs…DEFs of Immunotherapy in MS (CME) American Academy of Neurology, San Diego 2000 Multiple Sclerosis Update For Community Neurologists New Orleans, LA 2000 Advancement in MS Treatment Patient Program New Orleans, LA 2000 MS Research Update National MS Society San Antonio, TX


64

2000 MS Society Annual Keynote Lecture The Rationale for Early Treatment of MS Fargo, North Dakota 2000 MS Society Annual Keynote Lecture The Rationale for Early Treatment of MS Colorado Springs, CO 2000 New Advancement in Treating MS Multiple Sclerosis Association of America Little Rock, Arkansas 2000 The Rationale for Early Treatment of MS National MS Society Education Day Houston, Texas 2000 MS Update for Community Neurologists Fort Worth, Texas 2000 Treatment of MS:A Paradigm Shift Community Neurology Lecture Omaha, Nebraska 2000 Multiple Sclerosis/Vertigo

National Neurology & Psychiatry Board Review For Neurologists and Psychiatrists

Osler Institute, Houston, Texas 2000 Multiple Sclerosis Update National MS Society Education Day Little Rock, Arkansas 2000 Diagnosis & Treatment of MS:A Paradigm Shift Neurology Grand Rounds New Jersey Neuroscience Institute 2000 Update on MS and Evaluation of the Dizzy Patient Neurology for the Primary Practitioner Johns Hopkins Hospital 2000 MS Research, Past, Present, & Future MS Society Annual Research Day-Keynote Kansas City, MO 2000 Neuro-Ophthalmology of MS


65

Neurology Grand Rounds University of Iowa 2000 New Clinical Trial Data in MS For Community Neurologists Minneapolis, MS 2001 National MS Society Annual Education Lecture Lubbock, Texas 2001 National MS Society Annual Keynote Lecture Tulsa, Oklahoma 2001 Update on MS Treatment & Research Patient Education Program Denver, Colorado 2001 Keynote Lecture Annual MS Society Education Day Witchita, Kansas 2001 Multiple Sclerosis Patient Program St. Louis, MO 2001 Many Considerations of MS Program Chairman New York, NY 2001 Treating Multiple Sclerosis Brazilian Committee on Treatment & Research in MS Iguasu Falls, Brazil 2001 MS Update National MS Society Cheyenne, WY 2001 MS Update National MS Society Ft. Collins, CO 2001 Advances in MS Research National MS Society Sioux Falls, SD 2001 MS & Progression


66

Neurology Grand Rounds University of Kansas 2001 Neuro-Ophthalmology MS

Ophthalmology Grand Rounds University of Kansas

2002 Update on MS Research

USC Faculty MS Dinner

2002 Advances in the treatment & research of MS National MS Society Annual Keynote Lecture Los Angeles, California

2002 Advances in the treatment & research of MS Neurology Grand Rounds Northshore University, NY 2002 Advances in the treatment & research of MS Keynote Lecture-5th annual pateint education symposium St. Luke’s Roosevelt Hospital, NY 2002 Neuroradiologic measures of tissue injury in MS patients

with internuclear ophthalmoparesis (INO) Neurology Grand Rounds Scientific Institute Ospedale San Raffaele University of Milan, Italy

2002 Advances in the treatment & research of MS Kaiser Permanente 2002 Neurology Symposium Laguna Beach, CA

2003 MS Therapeutics:Evidence, Opinion, Standards of Care

Neurology Grand Rounds KU Medical Center, Kansas City, MO

2003 Neuroradiologic Measures of Tissue Injury in INO

Neurology Grand Rounds Charles University, Prague, Czech Republic

2003 Defining and Treating Breakthrough Disease in MS

Neurology Grand Rounds University of Iowa 2003 Advances in MS Research and Treatment


67

National MS Society Annual Meeting-Keynote Colorado Springs, Colorado

2003 Evidence, Opinion, and Intellectual Leaps in MS

National MS Society Meeting Amarillo, Texas

2003 Neuro-Ophthalmology Seminar Dept. of Neurology, KU Medical School Kansas City, MO 2003 Multiple Sclerosis Update KU CME Neurology Symposium 2003 National MS Society Teleconference Neuro-Ophthalmology of MS (National) 2003 Neuroradiologic Measure of Tissue Injury in MS Neurology Grand Rounds LSU School of Medicine 2003 Neuroradiologic Measures of Tissue Injury in MS Neurology Grand Rounds University of Tennessee, Memphis 2003 Update on MS National MS Society Annual Meeting New Orleans, LA 2003 MS:What do we know; What shoud we do? Keynote speaker National MS Society Annual Meeting Lone Star Chapter, San Antonio 2004 Keynote Speaker-MS Research National MS Society Annual Meeting Los Angeles, California 2004 Keynote Speaker-MS Update National MS Society Annual Meeting Las Vegas, Nevada 2004 MS Update University of Minnesota CME Program Minneapolis, MN


68

2004 Neuroradiologic measures of tissue injury in MS Neurology Grand Rounds Medical College of Ohio 2004 Neuroradiologic measures of tissue injury in MS Neurology Grand Rounds University of Pennsylvania 2004 Pathophysiology of MS Neurology Grand Rounds Charles University, Prague, Czech Republic 2004 Neuroradiologic measures of tissue injury in MS Neurology Grand Rounds Heinrich Heine University, Duesseldorf, Germany 2004 Eloquent Neuro-Ophthalmologic Models of Tissue Injury Neurology Grand Rounds University of Virginia 2004 New Research Findings in MS National MS Society Kenote Address Ft. Collins, Colorado 2004 Eloquent Neuro-Ophthalmologic Models of Tissue Injury Neurology Grand Rounds Virginia Commonwealth University 2004 Neuro-Ophthalmology of MS Neurology Grand Rounds Yale University 2004 Eloquent Neuro-Ophthalmologic Models of Tissue Injury Neurology Grand Rounds University of Connecticut 2004 MS Research Update National MS Society Keynote Speaker Fort Worth, Texas 2004 Eloquent Neuro-Ophthalmologic Models of Tissue Injury Neurology Grand Rounds Mayo Clinic (Scottsdale, AZ)


69

2005 MS:What do we know? What should we do? National MS Society Annual Keynote Lecture Lubbock, TX 2005 Professor’s Rounds Buffalo General Hospital State University of New York, Buffalo 2005 MS:Pathophysiologic Mechanisms Neurology Grand Rounds Univeristy of Groningen, Netherlands 2005 Eloquent Neuro-Ophthalmologic Models of Tissue Injury Neurology Grand Rounds Johns Hopkins Hospital 2005 Symptom Management of MS Brigham & Women’s Hospital Harvard Medical School 2005 MS Therapeutics Neurology Grand Rounds University of Kansas 2005 Eloquent Neuro-Ophthalmologic Models of Tissue Injury Neurology Grand Rounds LSU School of Medicine, Shreveport 2005 Eloquent Neuro-Ophthalmologic Models of Tissue Injury Neurology Grand Rounds University of Cincinatti 2005 Eloquent Neuro-Ophthalmologic Models of Tissue Injury Neurology Grand Rounds University of Missouri 2005 Eloquent Neuro-Ophthalmologic Models of Tissue Injury Neurology Grand Rounds University of Kansas 2005 MS Treatment Keynote Lecture National MS Society Lone Star Annual Meeting Houston, Texas


70

2005 MS Research Update Lahey Clinic Boston, Mass 2005 Eloquent Neuro-Ophthalmologic Models of Tissue Injury

Neurology Grand Rounds University of Missouri 2005 Multiple Sclerosis:What do we Know? MS International Federation (MSIF) Thessaloniki, Greece 2005 Pathophysiology of Multiple Sclerosis Washington State Neurological Society Annual Meeting Keynote Lecture 2005 Update on MS Research and Treatment National MS Society Annual Meeting Charlotte, NC 2005 Multiple Sclerosis Association of Rehab Nurses Annual Meeting Palm Springs, CA 2005 Models of Neuroprotection for MS Neurology Grand Rounds State University of New York at Syracuse 2006 The Anterior Visual System: A Model for Neuroprotection Neurology Grand Rounds Hackensack Hospital University of Medicine and Dentistry of New Jersey 2006 Pearls and Pitfalls of MS Management Neurology Grand Rounds University of Alabama (Birmingham) 2006 Update on Multiple Sclerosis

Medicine Grand Rounds Memorial Hosptial, South Bend, Indiana 2006 Neuro-Ophthalmology of MS Un-nerving Nystagmus Optic Neuritis and MS:To treat or Not Sally Letson Memorial Lectures


71

Ottawa, Canada 2006 Modeling Neuroprotection in MS Neurology Grand Rounds Albany Medical School 2006 Anterior Visual System in MS Neurology Grand Rounds Medical College of Virginia 2006 Models of Neuroprotection and Restoration for MS Neurology Grand Rounds State University of New York at Buffalo 2006 MS Research Update MS Society Annual Keynote Lecture Raleigh, North Carolina 2006 Epidemiology of MS MS Society Annual Keynote Lecture Baton Rouge, Louisiana 2007 Ophthalmologic Models of Neuroprotection in MS

Neurology Grand Rounds University of California at Davis

2007 Bowel, Bladder and Sexual Dysfunction in MS

Mayo Clinic Neurology National Review Course Scottsdale, Arizona

2007 Modeling Pathophysiology and Neuroprotection in MS Neurology Grand Rounds Charles University Prague, Czech Republic 2007 Neuro-Ophthalmology of MS Neurology Grand Rounds University of Basel, Switzerland 2007 What to do when DMAs Fail?

European Committee for Treatment and Research in MS Prague, Czech Republic Co-Chair with Dr. Gilles Edan (France)

2007 Neuroprotective Treatment Initiatives in MS


72

European Committee for Treatment and Research in MS Prague, Czech Republic Biogen Idec Research Symposium 2007 Management of Central and Peripheral Vertigo Symposium: Oculomotor abnormalities in MS Instituto Scientifico Universitario San Raffaele Milan, Italy 2007 Translating Molecular Mechanisms into Novel MS Therapy Neurology Grand Rounds University of Kansas 2007 Progress in the Management of MS

Neurology Grand Rounds University of Costa Rica, San Jose CR

2007 Multiple Sclerosis:What do we know? Neurology Grand Rounds Penn State University 2007 Modeling Neuroprotection in the Visual System Neurology Grand Rounds Dalhousie University, Halifax, Canada 2007 Modeling Neuroprotection for MS Montana Neurological Association Keynote Lecture 2007 Combination Therapy for MS:What do I do? Portugese Neurologic Association Coimbra, Portugal 2007 Selective Adhesion Molecule Therapy in MS Department of Neurology Clinical Rounds Wilford Hall, San Antonio (Lackland Airforce Base) 2007 A Think Tank on the Challenges of Treating MS Johns Hopkins CME National Teaching Course 2008 Visiting Professor of Neurology Grand Rounds Notre Dame and Montreal Neurologic Institute Montreal, Canada 2008 Modeling Pathophysiology and Neurodegeneration in MS


73

Neurology Grand Rounds University of California at San Diego 2008 Managing Symptoms in MS Neurology Grand Rounds Louisiana State University, Shreveport 2008 What is MS? Neurology Grand Rounds Royal Melbourne Hospital University of Melbourne, Australia 2008 Molecular Underpinnings of Progression in MS Neurology Postgraduate Symposium Sydney Australia 2008 Breakthrough Disease in MS Neurology Postgraduate Symposium Sydney Australia 2008 Retinal Architecture Predicts Pupillary Reflex Metrics Johns Hopkins MS Center Scientific Rounds Baltimore, Maryland 2008 Professor Rounds Department of Neurology Oregon Health Sciences University 2008 Diagnostic and Treatment Challenges In MS Neurology Grand Rounds University of Kansas 2008 The Eloquence of Efference Professor’s Rounds University of Kansas 2008 Modeling MS Pathophysiology in the Visual System Ophthalmology Grand Rounds University of Kansas 2008 The Eloquence of Efference Vision and MS Course (CME) International MS Meeting (ECTRIMS/ACTRIMS/LACTRIMS) Montreal, Canada


74

2008 Modeling Neurodegeneration and Pathophysiology of MS In the Eye. Neurology Grand Rounds University of Massachusetts 2008 Modeling Pathophysiology and Neuroprotection in MS American Academy of Physical Medicine and Rehabilitation San Diego, California 2009 The Eloquence of Efference and Afference in MS Neurology and Ophthalmology Grand Rounds Michigan State University 2009 Neuro-Ophthalmologic Models of Pathophysiology and Neuroprotection in MS Neurology Grand Rounds Emory University, Atlanta Georgia 2009 Neuro-Ophthalmology in MS Distinguished Visiting Professor of Neurology Charles University Shool of Medicine Prague, Czech Republic 2009 Venous Function in MS Chronic cerebrospinal venous insufficency (CCSVI) Co-Chairman An International Coterie Bologna, Italy 2009 Management of symptoms in MS European Committee for Resarch and Treatment in MS Dusseldorf Germany 2009 Assessment and Treatment of Sexual Dysfunction in MS European Committee for Resarch and Treatment in MS Dusseldorf Germany 2009 Update on MS Department of Neurology CME Symposium University of Kansas 2009 Neuroprotection in MS:Can it be done? Hawaiian Neurological Society Oahu, Hawaii


75

2009 MS Ocular Motor Pathophysiology Neurology Grand Rounds Case Western Reserve University 2009 Emerging Therapies for MS and NMO Department of Neurology Residency Lecture University of Utah (Salt Lake) 2009 Northwestern Neurology Resident Symposium Ft. Lauderdale, Florida 2009 Neuroprotection in MS Department of Neurology Grand Rounds Cleveland Clinic Florida 2010 1. Management of Symptoms in MS 2. Emerging Immunotherapy for MS Heinrich Heine University, Duesseldorf, Germany 2010 Translating Immunopathogenesis into Immunotherapy University of Puerto Rico (MS CME Symposium) 2010 Emerging Treatment for MS Neurology Grand Rounds Virginia Commonwealth University 2010 NeuroFlash MS-Chairman American Academy of Neurology Toronto, Canada 2010 Modeling Axonal Degeneration in MS American Society of Neurochemistry Sante Fe, New Mexico 2010 Modeling Neurodegeneration in MS Neurology Grand Rounds Oregon Health Sciences University 2010 Update on Multiple Sclerosis Saint Elizabeth’s Hospital Boston, Mass 2010 Update on Multiple Sclerosis MS Center University of Massachusetts


76

2010 Structure-Function Studies of the MLF in INO Mellen MS Center Morning Rounds Cleveland Clinic 2010 Neurology Resident Case Presentations Department of Neurology Cleveland Clinic 2010 4-Aminopyridine for Multiple Sclerosis Madrid Spain 2010 Emerging MS Therapies:Risks and Benefits Hawaiian Neurology Association Annual Meeting Oahu, HI 2010 Update on MS Treatment National MS Society Annual Meeting Montana 2010 Treating MS Tulane Neurology Symposium New Orleans, LA 2010 Symptom Management of MS European Committee for Treatment and Research in MS Gottenberg, Sweden 2010 Update on MS Research and Treatment Kentucky MS Annual Meeting Louisville, KY 2010 Multifocal Evoked Potentials in MS Neuroimmunology Rounds Johns Hopkins Hospital 2010 Neuroprotection in the Visual System Neuroimmunology Group Lecture Ohio State University 2010 Pathology and Pathophysiology of MS Update on the Management of MS Northwestern University CME Chicago, Illinois


77

2011 ‘Eye-ing’ a Window of Neuroprotection for MS Neurology Grand Rounds Johns Hopkins Hospital 2011 ‘Eye-ing’ a Window of Neuroprotection for MS Neurology Teaching Rounds University of Maryland 2011 Diffusion Tensor Imaging of the MLF in INO Tribute to Dr. John Leigh Ocular Motor Symposium Buenos Aires, Argentina 2011 Pupillary reflex metrics in MS:Objective Characterization of the afferent pupillary defect Vision in MS Section Platform Presentation American Academy of Neurology Honolulu, Hawaii 2011 Vision Scientific Session Session co-Chairman with Ari Green American Academy of Neurology Honolulu, Hawaii 2011 ‘Eye-ing a Window of Neuroprotection for MS Neurology Grand Rounds Ochsner Medical Center New Orleans, LA 2011 What is MS? American Association of Physician Assistants Annual Meeting Keynote Lecture (with Teresa Frohman) Las Vegas, Nevada 2011 Multidisciplinary Management of MS German Neurological Society Dussesdorf, Germany 2011 ‘Eye-ing a window of Neuroprotection for MS Neurology Grand Rounds Heinreich Heine School of Medicine Dusseldorf, Germany 2011 ‘Eye-ing a window of Neuroprotection for MS Neurology Grand Rounds School of Medicine


78

Muenster, Germany 2011 “Eye-ing” a window of neuroprotection for MS Neurology Grand Rounds Providence Hospital System Portland, Oregon 2011 Characterizing Uhthoff’s Phenomenon in MS Neurology Rounds Texas Tech School of Medicine 2011 The Optic nerve head component in MS ECTRIMS Amsterdam, Netherlands 2011 Thermal modulation of axonal channels in MS ECTRIMS Amsterdam, Netherlands 2012 “Eye-ing” a window of neuroprotection in MS Neurology Grand Rounds University of California Los Angeles (UCLA) 2012 “Eye-ing” a window of neuroprotection in MS National Annual Keynote Lecture The National Multiple Sclerosis Society New York City, New York 2012 “Eye-ing” a window of neuroprotection in MS Neurology Grand Rounds KU Medical School 2012 Modeling MS in the Eye Stanley van den Noort Memorial Lecture University of California at Irvine 2012 Update on MS Medicine Grand Rounds Quad Cities Illinois 2012 Neuroprotection in MS:Can it be done? Stanley Waterman Memorial Lecture National MS Society Annual Meeting New England Region


79

2012 Update on MS Treatment International Neurorehabilitation Meeting Vancouver, Canada 2013 ‘Eye-ing a Window of Neuroprotection in the Visual System for Multiple Sclerosis Keystone Keynote Lecture Big Sky Montana 2013 The Ins (Na+) and Outs (K+) of the Ion Channel Pathophysiology of the Demyelinating Axonopathy in MS Neurology Grand Rounds Lehigh Valley Health Network Lehigh Pennsylvania 2013 Pathobiological Underpinnings of MS and it’s Translation into Disease Modifying Therapy Capra Research Symposium UT Southwestern Medical Center 2013 MS and Neuroimmunology Rounds Johns Hopkins Hospital 2013 New York University Grand Rounds 2013 Melanopsin Mediated Pupillary Light Reflex as a Signature Surrogate Biomarker for the Retinohypothalamic tract in MS Ophthalmology Grand Rounds University of Iowa 2013 Advances in the Diagnosis and Treatment of MS Texas Neurologic Society Winter Conference Austin Texas 2013 Update on MS Treatment Annual Methodist Hospital Neurology Review Houston Texas 2013 The Eye as a Window for the development of Novel Treatments for MS Neurology Grand Rounds University of Minnesota 2013 International Conference on Vision and


80

Vision-Related Outcomes in MS Co-Chair with Dr. Giancarlo Comi on Paraclinical Assessment of Visual Impairment Sponsored by the National MS Society A ‘White Paper’ will be produced soon Dublin,Ireland 2014 The Eye in MS: A Portal into Dissecting Mechanisms of CNS Disorders Neurology Grand Rounds The Royal Melbourne Hospital Melbourne, Australia 2014 The Melanopsin-Mediated Pupillary Light Reflex As a Surrogate Signature Biomarker for the Retinohypothalamic Tract in MS Neurology Grand Rounds The Royal Prince Albert University Sydney, Australia 2014 The Elegance of Eloquence in MS Plaque Pathogenesis: Protons, Protection, and the Prospects for Plasticity Donald Paty Memorial Lecture Consortium of MS Centers (CMSC) Dallas, Texas 2014 The ‘Achilles Heel’ of Selective Adhesion Molecule Inhibitors:Bone Marrow Mobilization of “MAD-ness” In the ‘Trojan Horse’z�:Corroboration of the Outside-In Pathoetiologic Mechanism for PML. National Institutes of Health & NINDS Special Symposium on 30 Years of PML Research In Honor of Dr. Eugene O. Major Invited Speaker 2014 Update on MS Therapy Department of Neurology Lunch Lecture University of Miami 2014 The Elegance of Eloquence in the Visual System for MS Charcot Foundation Keynote Lecture Baveno, Italy


81

2015 Modeling MS Mechanisms of Disease in the Visual System Neurology Grand Rounds The Salpetriere Hospital Paris, France


82

Fellows and Students

1. Hui-Juan Zhang, M.D., Ph.D. (one of our former Chief Residents) was a clinical fellow in the MS group from July 2000 through June 2001. She was offered a faculty position in the department of neurology at UT southwestern, but declined when her husband was unable to obtain a Texas License. She is currently in private practice in Washington State and directs a comprehensive community based MS Program.

2. Amber Salter, BA, worked in the MS Program during summers while at UT Austin for undergraduate studies. She went on to complete a masters in public health and then joined our group as a research associate from 2005-2008. She entered the biostatistics training program at the University of Alabama in 2008 with Dr. Gary Cutter. She was the recipient of the Best Young Investigator Poster Award at the American Committee for the Treatment and Research of MS (ACTRIMS) in 2007.

3. Of the 250 neurology residents that have completed the US Congressionally sponsored MS Comprehensive treatment training program, 24 decided to pursue either MS or neuroimmunology fellowships. A number of these are now MS Program Directors at academic institutions.

4. We have had a multitude of neurology resident and medical student rotators work with us in the MS Clinical Center or in our various neuroimmunology research laboratories.

5. Heather Winslow, M.D.-Clinical Post-Doctoral Fellow from July 2004 to June 2005. Project involved the development of validation of OCT for optic neuropathy in MS. In collaboration with Laura Balcer (UPENN). Heather was instrumental in establishing the OCT laboratory at UT Southwestern Medical Center in the MS Clinical Center and has served as co-author and principal author on a number of peer review publications. She is completing ophthalmology residency training at UT Southwestern Medical Center.

6. Douglas Woo, M.D. Chief Resident at Medical College of Wisconsin. Served as a National MS Society Funded Fellow at our Center 2005-2006. He returned to the Medical College of Wisconsin to serve as Director of the MS Program as well as Director of the Neurology Residency Training Program.

7. Douglas Mills, B.A. was a student research associate for 2006/2007 from Washington University St. Louis. During his tenure with us, he conducted studies on the changes in eye movement physiology of MS patients during heating and cooling experiements. His work has also focused on the safety implications of these studies on driving and walking. His work was published (he served as first author) in the journal Neurology. Currently he is in medical school in Chicago.


83

8. Angela Bates, M.D. Chief Resident at UT Southwestern. NMSS fellowship awarded for 2007/2008. Currently Assistant Professor of Neurology at UT Southwestern Medical Center.

9. Wanda Castro, M.D., Chief Resident at U of Connecticut. NMSS fellowship awarded for 2007/2008. Following her role as Instructor and later Asst. Professor of Neurology at UT Southwestern Medical Center, she moved on to become the Director of the MS Program at the University of Connecticut.

10. Gina Remington, BS, RN. – John Dystel NMSS Nursing Fellowship Award- 2007. Currently Senior Research and Clinical Nurse at UT Southwestern Medical Center. Recent recipient of the prestigious UT Southwestern Medical Center Strauss Award.

11. Ryan Winger-an undergraduate summer student from Ohio is focused on laboratory studies involving amyloid protein studies with Drs. Olaf Stuve and Roger Rosenbert.

12. Scott McMclure, a UT Austin undergraduate pre-medical student, he wil complete a summer fellowship with us. His work focused on ocular motor pathophysiology of MS, and on autonomic pathophysiology in MS under the direction of Dr. Scott Davis. He co-authored a research paper withour group based on this work. Currently he is a second year resident in Emergency Medicine at UT Southwestern Medical Center.

13. Erik Burton, M.D., Senior Resident at UT Southwestern. NMSS fellowship awarded for 2008/2009. Recetly awaded a Harvard Partner’s Fellowsip for $120,000 for two years of training. He has also been awarded a TEVA Neuroscience clinical fellowship for 2009/2010. He joined the UT Southwestern Medical Center Scholars Program in 2009/2010. Subsequently he joined the MS Center at the University of New Mexico.

14. Melissa Korkmass, B.A., Ocular motor and autonomic research associate 2007-2010. Melissa will enter the Physician Assistant Program at Duke University in July 2010.

15. Ardith Courtney, D.O., NMSS fellowship awarded for 2008/2009. Following her tenure with us as Asst. Professor of Neurology from 2009 till 2012, she became Director of the MS Program at the University of California at Irvine.

16. Donna Graves, M.D., MS Fellow 2009/2010 (from St. Louis University) 17. Jason Silversteen, D.O., MS Fellow 2009/2010 (from Drexel University).

Following fellowship he was appointed Director of the MS Program 18. Amanda Studebaker, Texas Academy of Math and Science High School

Summer student Sholarship Program for 2009. Following her tunure with us Amanda attended Rice University in 2010.

19. Paul Blazek, UT Southwestern Medical Center STARS Program Summer High School Student (2009 and 2010). Paul currently attends the University of Pennsylvania in 2010. His work with us for two consecutive


84

summer fellowship training periods culminated in the following platform presentation at the American Academy of Neurology in 2011 (Hawaii); "Pupillary Reflex Metrics in MS: Objective Characterization of the Afferent Pupillary Defect (APD)". Subsequently Paul served as 1st author on a paper published in Neurology entitled ‘Objective Characterization of the relative afferent pupillary defect in MS.’

20. Adnan Subei, D.O., MS/Neuro-Ophthalmology Fellow from Michigan State, he spent 2009/2010 as a post-graduate (medical school) clinical research fellow before returning back to Michigan State for neurology residency. He helped design and excute a novel study utilizing wavelength restricted light therapy to treat fatigue in MS.

21. Diana Logan, RN, CNP. John Dystel NMSS Nursing Fellowship Award- 2009. Recipient of the first UT Southwestern Medical Center Nurse Practitioner Award. Diana is the architect of the Center’s Total Life Care (TLC) Clinic; a multidisciplinary initiative developed on behalf of our most complex MS patients and their families. She was the recipient of the ‘Best Platform Presentation’ at the 2012 meeting of the Consortium of MS Centers. More recently she was the recipient of the highly coveted Strauss Award for 2012/2013, which recognizes excellence in nursing, patient advocacy, and innovative development of novel programs that seek to better serve our deserving patients.

22. Audrey Frohman-A high school summer research student helped to establish our multifocal visual evoked potential (mfVEP) laboratory in the summer of 2010. Audrey presented her work as a lecture at the weekly Neuroimmunology section meeting at Johns Hopkins in August 2010. Her work in conjunction with Zane Schnurman led to the following presentation at the American Academy of Neurology in 2011 (Hawaii); "Pattern Reversal Multifocal Visual Evoked Potential Timing (Latency) and Amplitude Cortical Responses Are Contingent upon Stimulus Contrast in Patients with Multiple Sclerosis." This work led to a peer-reviewed manuscript published in Neurology, and triggered the lead editorial authored by Dr. Matthew Thurtell (U of Iowa) and Dr. Steven Galetta (Chairman of Neurology, New York University).

23. Zane Schnurman-A first year college student from Brandeis University served as a summer research student working in conjunction with Audrey Frohman on the establishment of our mfVEP laboratory. Their collaborative work resulted in the following presentation at the American Academy of Neurology in 2011 (Hawaii); "Pattern Reversal Multifocal Visual Evoked Potential Timing (Latency) and Amplitude Cortical Responses Are Contingent upon Stimulus Contrast in Patients with Multiple Sclerosis." Zane returned to Brandeis and was nominated for the Barry Goldwater Fellowship Award based on his productive scientific work in our group. He subsequently joined our group as an undergraduate by transferring from Brandeis to the University of Pennsylvania in the fall


85

of 2011. He puplished his work regarding the optic nerve head component of the mfERG in Neurology 2014;82:1888-1896. He is attending medical school at New York University (August 2013).

24. Audrey Bartosh-A summer research student from Vanderbilt University joined us in 2010 to help facilitate our research investigation entitled Wavelength Restricted Light Therapy for Fatigue in Multiple Sclerosis: A Pilot Study. Following her tenure with us, Audrey transferred to SMU.

25. Carmen Lopez-A summer research student from Notre Dame. Carmen worked in our laboratory during the summer of 2011, 2012, taking on the role of principal coordinator for the STRATIFY study, characterizing the JC virus IgG status of patients being treated with natalizumab. Following graduation from Nortre Dame Carmen returned to serve as a clinical trial coordinator on the ACTHAR vs Methylpredisolone acute Optic Neuritis trial with us for the 2013/2014 academic year. She will attend medical school in the fall.

26. Monica Blazek-A summer high school student who worked in the laboratory of Dr. Nancy Monson for the summer of 2011, and funded by the MS Program. Monica worked on B cell immunology studies related to the immunopathogenesis of MS.

27. Lindsay Horton-A UT Southwestern Medical Student who was awarded a one-year Doris Duke Fellowship, worked in our neuro-ophthalmology research laboroatory for a year (2011-2012) under the direct supervision of Dr. Benjamin Greenberg and my neuro-ophthalmology team (myself, Amy and Darrel Conger, and Teresa Frohman). Her work is focused on the role of aminopyridines in the pathophysiology of MS within the anterior visual system, and was published this year in the journal Neurology, and entitled ‘The Effect of 4-aminopyridine on Vision in MS patients with Optic Neuropathy’. Lindsay was the winner of the 2013 Department of Neurology Prize for best student and the American Academy of Neurology Medical Student Prize for Excellence in Neurology.

28. Ethan Meltzer-A medical student at UT Southwestern Medical Center who has joined with his classmate and collaborator, Peter Squigny, to develop a novel wave-adjustable ligtht-stimulation device for the purpose of activating the retinohypothalamic tract system; and to ultimately develop clinical trial initiatives focused on the treatment of fatigue, depression, and derangements of neuroendocrine reflex arcs, secondary to CNS degenerative disorders such as MS. Ethan presented his work at the Keystone MS meeting in February at Big Sky Montana. Ethan was the recipient of the 2013 Medical Student Research Prize from the Consortium of MS Centers. He, in collaboration with another medical student, Peter Sguigna, presented their work at MS and Neuroimmunology Rounds at Johns Hopkins, and Department of Neurology Grand Rounds at NYU the very next day. Both Ethan and Peter had their abstract accepted


86

for presentation at the European Committee for Treatment and Research in MS (ECTRIMS) in Copenhagen Denmark, in October of 2013. Ethan and Peter were awarded one of five (out of ~2000 submitted abstracts) “Best MS Research” Prizes for 2013.

29. Peter Squigny- A medical student at UT Southwestern Medical Center who has joined with his classmate and collaborator, Ethan Meltzer, to develop a novel wave-adjustable ligtht-stimulation device for the purpose of activating the retinohypothalamic tract system; and to ultimately develop clinical trial initiatives focused on the treatment of fatigue, depression, and derangements of neuroendocrine reflex arcs, secondary to CNS degenerative disorders such as MS. Peter presented his collaborative work with Ethan Meltzer at the Keystone meeting on MS in February 2013, and subsequently at both Johns Hopkins and NYU. Peter was the recipient of the 2013 Medical Student Research Prize from the Consortium of MS Centers. Both Ethan and Peter had their abstract accepted for presentation at the European Committee for Treatment and Research in MS (ECTRIMS) in Copenhagen Denmark, in October of 2013. Ethan and Peter were awarded one of five (out of ~2000 submitted abstracts) “Best MS Research” Prizes for 2013.

30. Ethan Meltzer and Peter Squigna recently were awarded the The American Academy of Neurology; Neurology Award (the first time this coveted award has been bestowed upon two students). The joint award recognizes the unique nature of the collaboration among these two students.

31. Shin Josh Beh-A neurology resident at UT Southwestern Medical Center who has been participating in our research intitiatives since 2011. He recently delivered a platform presentation at the American Academy of Neurology describing his work in our laboratory on the optic nerve head component of the mfERG. He was awarded the Fred Baskin Award for the most promising young investigator at UT Southwestern Medical Center. He also was awarded ‘Best Resident Teacher’. Josh completed a two-year fellowship in July 2012-2014, where he spent 8 months at UT Southwestern Medical Center, 8 months at Johns Hopkins, and 8 months at the New York University. He is the first fellow to be trained within the context of our multicenter vision research collaboration. He is a recipient of a Biogen Idec Fellowship Award for 2012. Having achieved an O-1 VISA, Josh will join our faculty as Assistant Professor of Neurology, and Director of Vestibular Neurology and MS Neuro-Ophthalmology.

32. Marlen and Mirna Lucero-Undergraduate students who worked in our eye laboratory for the summer of 2012 and 2013, focused on mfERG studies. Marlen returned to spend the entire year conducting research with us for 2014-2015.

33. Ashley Frohman, a college senior at Texas Tech this fall, has worked our laboraory this summer, specifically organizing our heating and cooling


87

studies involving MS patients with a history of acute optic neuritis and internuclear ophthalmoparesis. Ashley recently worked on a monograph and video series on Aquatic Therapy in MS for the MS Association of America (MSAA), where she servied as 1st author. Ashley and her laboratory partner, Derek Sears, are the first exchange students as part of the Dallas-Melbourne Collaborative MS and Cognition Alliance. She and Derek spent the first half of a 12 week summer student Fellowship at the Royal Melbourne University Hospital.

34. Derek Sears, a medical student at Texas Tech Medical School in El Paso. Derek Sears and Ashley Frohman, are the first exchange students as part of the Dallas-Melbourne Collaborative MS and Cognition Alliance. Derek spent the first half of a 12 week summer student Fellowship at the Royal Melbourne University Hospital. In the spring of 2014 Derek was the recipient of the 2013 Medical Student Research Prize from the Consortium of MS Centers.

35. Benjamin Frohman, a recent high school graduate, has joined our summer student research initiative, where he has been working on our melanopsin studies in collaboration with Ethan Meltzer and Peter Sguigna.

36. Sara Qureshi recently joined us from Albert Einstein Medical College in New York, and was awarded a National Multiple Sclerosis Society Fellowship for 2013-2014.

37. Richard B. Dewey, Jr. III is a 1st year medical student who was recently awarded a UT Southwestern Medical Student Summer Research Award. He will be working in our laboratory (Dr. Frohman serving as mentor) on the melanopsin pathway derangements in MS. Richard was recipient of the 2013 Medical Student Research Prize from the Consortium of MS Centers.

Faculty Recruitments

1. Dr. Michael Racke was recruited from Washington University in St. Louis in 1999. He was promoted to full Professor with Tenure while here at Southwestern. He was appointed Chairman of Neurology and Director of the Neuroscience Research Institute at Ohio State University in 2006. He is widely recognized as one of the most accomplished neuroimmunologists in the world today.

2. Dr. Kathleen Hawker-was recruited as a clinician investigator Assistant Professor of Neurology in 2001. She moved to Ohio to get married in June of 2005 and subsequently joined Dr. Michael Racke as an Associate Professor of Neurology at Ohio State University. More recently she has moved to Eli Lilly as a medical science director for MS clinical trials. She served as the principal investigator of the rituximab in primary progressive clinical trial (Olympus Trial).

3. Dr. Olaf Stuve was recruited by Dr. Racke and myself to UT Southwestern in 2004 from UCSF to serve as a physician investigator. His work is focused on neuroimmunology and the development of clinical trial initiatives. He is currently


88

Associate Professor of Neurology and Neurotherapeutics at UT Southwestern Medical Center, and serves as the Director of the Neurology section at the Dallas VA Hospital.

4. Dr. Anjali Shah was recruited as Assistant Professor of PM&R and Neurology from the University of Washington in Seattle in the fall of 2005 to assume the Directorship of MS Neurorehabilitation. Dr. Shah is a physical medicine and rehabilitation specialist. She completed an MS Fellowship with Dr. George Kraft at the University of Seattle in Washington. She is currently focused on MS Neurorehabilitation.

5. Dr. Scott Davis was recruited as Assistant Professor of Neurology in September of 2006 from the Exercise and Physiology Institute at Presbyterian Hosptial in Dallas. He directs our MS Neurophysiology research program. Dr. Davis has focused on autonomic abnormalities in MS and the role of thermoregulation and its impact upon vision and other areas of functional performance. Currently he is Associate Professor of Physiology at Southern Methodist University, and is adjunct Associate Professor of Neurology and Neurotherapeutics at UT Southwestern Medical Center.

6. Dr. Todd Eager was recruited as Assistant Professor of Neurology in 2006 from UCSF where he worked in Jeff Bluestone’s laboratory on the NOTCH signalling pathway. His work is focused on modeling inflammatory mechanisms of demyelination, neurodegeneration, and neuroprotection and remyelination.

7. Dr. Angela Bates-Flores, our former Chief Resident in neurology (2007), she joined us as an NMSS sponsored clinical fellow, followed by assumming the faculty position of Instructor in 2008. She was subsequently promoted to Assistant Professor.

8. Dr. Ardith Courtney joined our faculty as Assistant Professor of Neurology upon the completion of her NMSS MS Fellowship. She is now Director of the MS Program at the University of California at Irvine.

9. Dr. Wanda Castro joined our faculty as Instructor of Neurology after completing her NMSS MS Fellowship. She is now the Director of the MS Program at the University of Connecticut.

10. Dr. Benjamin Greenberg joined our group as Assistant Professor from Johns Hopkins in January 2009 and serves as the Cain Denius Scholar in MS, and Director of the Transverse Myelitis and Neuromyelitis Optica Programs. He is also Deputy Director of the MS Program and Director of our new Neuroimmunology Biomarker Development Program. He will organize a new hosptial-based neuroimmunology consultation service spanning both adult and pediatric populations. A Pediatric Eye Research Program is soon to be established at the Children’s Hospital of Dallas.

11. Dr. Erik Burton is a former UT Southwestern neurology resident. He is completing an NMSS funded fellowship for 2008/2009. He joined our MS Program faculty as Assistant Professor of Neurology and participated in the UT Southwestern Medical Center Scholars program. In 2012 he joined the University of New Mexico as Assistant Director of the MS Program.

12. Dr. Jeffrey Orstadt is a sleep specialist from Northern California. I assisted the Department of Neurology with his recruitment. Since his arrival he has become involved in research studies focused on sleep derangements in MS.


89

13. Dr. Donna Graves served as an NMSS funded fellow at our Center for 2009/2010. She joined our faculty in July 2010 as Assistant Professor of Neurology and Deputy Director of the Pediatric Demyelinating Disease Program at the Dallas Children’s Hospital.

14. Dr. Shanan Munoz recently joined our group as an MS clinical specialist. 15. Dr. Darin Okuda recently joined our team as a clinician investigator, and has been

officially recruited as Director of MS Imaging Research, and recently accepted the position of Deputy Director of the MS Program.

16. Teresa C. Frohman, PA-C has the longest standing role both in my clinical care, research, and teaching career. She worked with me to both architect and write the 2000 United States Congressional Bill that established the National MS Treatment Training Program, in collaboration with the National MS Society. From the inception of the Program, Teresa has served as the Executive Director of this National Training initiative. She has also served as the Executive Director of the MS Program and the Clinical Center for MS; since its inception. An author of many peer-review manuscripts, she served as senior Editor of the National MS Society commissioned book entitled “Multiple Sclerosis for the Physician Assistant”. Teresa recently published the first characterization of the optic nerve head component (ONHC) response in MS, in the journal Neurology. This article garnered a lead editorial in the August 6th 2013 issue of Neurology in addition to an on line PodCast from the American Academy of Neurology. She has served as the senior author on what has been widely recognized as the seminal paper on the MLF in ocular motor physiology. Teresa has lectured throughout the world, including delivering Neuroimmunology or Neurology Grand Rounds lectures at KU, Johns Hopkins, NYU, and the University of Iowa. Recently she was invited to lecture at the highly prestigious MS Center at the Brigham and Women’s Hospital at Harvard Medical School. Teresa’s reputation as a passionate, humanistic and dedicated care provider for MS patients and families, and as an emerging clinical investigator and educator is skyrocketing. She was recently invited to lecture on symptom management in MS at the American Academy of Neurology meetings (she will serve as the first PA to serve on the teaching faculty at the AAN). Teresa was recently awarded the coveted UT Southwestern Medical Center Strauss Award, for her excellence in clinical care.

17. Dr. Josh Beh has served as our neurology resident and two-year, 3-Center MS Fellow. Josh was awarded an O-1 Visa in the spring of 2014, and will join our faculty as Asst. Professor of Neurology and Neurotherapeutics, and will serve as Director of Vestibular Neurology & MS Neuro-Ophthalmology

VIDEO TEACHING PRODUCTIONS: 2000 Evaluation of the Dizzy Patient Scientific American Medicine 2000 Sexual Health in Multiple Sclerosis 2004 Interactive Network for Continuing Education


90

Multidisciplinary MS Slide Set and Video Series For National Distribution Chairman 2004-2007 Interactive Network for Continuing Education Emerging Therapeutic Options:Advancing Strategies for Multiple Sclerosis. Slide Set and Video Series on Selective Adhesion Molecule Inhibitors (SAMi). For National Distribution Chairman 2005- Eye Movement Assessment in Neurology An animated computer-based teaching course 2009 My MS Yoga A Collaborative Program with Baron Baptiste 2014- Aquatic Therapy Training for MS MS Association of America MEDICAL JOURNALISM: 1995 News 4 Texas 1999 News 4 Texas 1997 Perspectives-PBS Quad Cities, Illinois 1998 Good Morning Texas 1999 News 4 Texas-MS:New Treatments 2000 News 4 Texas-MS Update 2004 WB 33 –MS Update on Research & Treatment 2010 MyMSYoga-Good Morning America 2012 PBS ‘Health Minds Healthy Bodies’ (pending release)

Special Episode on MS (showcasing of UT Southwestern Medical Center’s Clinical Center for Multiple Sclerosis

Documents

Elliot M. Frohman, M.D., Ph.D. - UT Southwestern Medical ... Elliot Frohman.pdf · Accelerated Cure Project for Multiple Sclerosis Boston, MA 2012-14 US News and World Report Top